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                                 1. INTRODUCTION 
1.1TABLETS
 (1,2)
 
Definition: Tablets are tamperproof solid unit dosage forms containing medicament 
or mixture of medicaments and excipients compressed or molded into solid 
cylindrical shape having either flat or convex surfaces. 
 
1.2 Properties of tablets 
The attributes of an acceptable tablet are as follows: 
 The tablet must be sufficiently strong and resistant to shock, abrasion, should 
withstand handling during manufacturing, packing, shipping, and use. 
Hardness and friability tests measure this property. 
 Tablet must be uniform in weight and in drug content of the individual tablet. 
This is measured by the weight variation and content uniformity tests. 
 The drug content of the tablet must be bioavailable. This property is measured 
by the dissolution test. Accurate bioavailability can be obtained from the drug 
levels in the blood after its administration. 
 Tablets must be elegant in appearance, characteristic shape, color and other 
markings necessary to identify the product. 
 Tablets must retain all these functional attributes which include drug stability 
and efficacy. 
 
1.3 ADVANTAGES AND DISADVANTAGES 
Advantages 
 Offers greatest capability of all oral dosage forms for the greatest dosage precision 
&Good content uniformity.  
 High patient compliance. 
 Their cost is lowest of all dosage forms 
 One of the major advantages of tablet over capsules is that the tablet is essentially 
“tamperproof dosage form”. 
 Easiest and cheapest to packaging and shipment 
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 They are having best combined properties of chemical, mechanical and 
microbiological properties 
 Accuracy of dose is maintained since tablet is a solid unit dosage forms 
 Longer expiry period and minimum microbial spillage owing to lower moisture 
content 
 Large scale manufacturing is feasible in comparison to other dosage forms. 
Therefore, economy can be achieved. 
 Organoleptic properties (taste, appearance, and odor) are improved by coating of 
the tablets. Product identification is easy and marketing done with the help of 
grooved punches and printing with edible ink. 
 As a tablet is not a sterile dosage form, stringent environmental conditions are not 
required in the tablet department. 
 
Disadvantages 
 Some drugs resist compression owing to their amorphous nature & low density 
character. 
 Drugs with poor wetting, slow dissolution property, large dosages or any 
combination of these features may be difficult or impossible to formulate & 
manufacture as a tablet. 
 It is difficult to convert a high dose poorly compressible API into a tablet of 
suitable size for human use. 
 Slow onset of action as compared to parenterals, liquid orals and capsules. 
 The amount of liquid drug (e.g., vitamin E, Simethicone) that can be trapped into 
a tablet is very less. 
 Difficult to swallow for kids, terminally ill and geriatric patients. 
 Patients undergoing radiotherapy cannot swallow tablet. 
 
1.4 TYPES AND CLASSES OF TABLETS
(2) 
Tablets are classified by their route of administration or function, by the type of drug 
delivery system they represent within that route, by their form and method of 
manufacture. 
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1.4.1 TABLETS INGESTED ORALLY 
(a) Compressed tablets 
These tablets are uncoated and made by compression of granules. These tablets are 
usually intended to provide rapid disintegration and drug release. These tablets 
contain water-soluble drugs, which after swallowing get disintegrated in the stomach, 
and its drug contents are absorbed in the gastrointestinal tract and distribute in the 
whole body. 
 
(b) Multiple compressed tablets  
These tablets are prepared to separate physically or chemically incompatible 
ingredients or to produce repeat action prolonged action products. To avoid 
incompatibility, the ingredients of the formulation except the incompatible materials 
are compressed into a tablet then incompatible substances along with necessary 
excipients are compressed tablet. 
 
(c)Multilayered tablets 
These tablets consist of two or more layer of materials compressed successively in the 
same tablets. The color of each layer may be the same or different. The tablets having 
layers of different colours are known as "multicoloured tablets". 
 
(d) Sustained action tablets  
These tablets are used to get a sustained action of medicament. These tablets when 
taken orally release the medicament in a sufficient quantity as and when required 
maintaining the maximum effective concentration of the drug in the blood throughout 
the period of treatment 
 
(e) Enteric-coated tablets 
These are compressed tablets meant for administration by swallowing and are 
designed to bypass the stomach and get disintegrated in the intestine only. These 
tablets are made to release the drug undiluted and in the highest concentration 
possible within the intestine. Eg: tablets containing anthelmentics, and amoebic id 
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(f) Sugar coated tablets 
The compressed tablets having a sugar coating are called " sugar coated tablets". 
 
(g) Film coated tablets 
Application of thin polymer based coatings to tablet/granules by a spray atomization 
technique. Thickness of such coating is usually between 20-100µm . 
 
(h) Chewable tablets 
These tablets are chewed in the mouth and broken into small pieces. In this way, the 
disintegration time is reduced and the rate of absorption of the medicament is 
increased. e.g.: aluminium hydroxide tablets, and phenolphthalein tablets. 
 
1.4.2 TABLETS USED IN ORAL CAVITY 
(a) Buccal tablets 
These tablets are to be placed in the buccal pouch or between the gums and lips or 
cheek where   they dissolve or disintegrate slowly and are absorbed directly without 
passing into the alimentary canal. Eg: tablets of ethisterone 
 
(b) Sublingual tablets 
These tablets are to be placed under the tongue where they dissolve or disintegrate 
quickly and are absorbed directly without passing into GIT.  
Eg: tablets of glyceryl trinities. 
 
(c) Lozenge and torches  
These tablets are designed to external local effect in the mouth or throat. These tablets 
are commonly used to treat sore throat or to control coughing in common cold. They 
may contain local anaesthetics antiseptic, antibacterial agents, astringent and 
antitussives. 
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1.4.3 TABLETS USED TO PREPARE SOLUTION
(2) 
(a) Effervescent tablets  
In addition to the drug substance, these contain sodium bicarbonate and an organic 
acid such as tartaric acid or citric. In the presence of water, these additives react, 
liberating carbon dioxide that acts as disintegrator and produces effervescence. Except 
for small quantities of lubricants present, effervescent tablets are soluble. Tablet 
triturates usually are made from moist material, using a triturate mild that gives them 
the shape of cut sections of cylinder. Such tablets must be completely and rapidly 
soluble, The problem arising from the compression of these tablets is the failure to 
find a lubricant that is completely water-soluble. 
 
(b) Dispensing tablets 
These tablets provide a convenient quality of potent drug that can be incorporated 
readily in to powders and liquids, thus circumventing the necessity to weigh small 
quantities. These tablets are, supplied primarily as a convenience for extemporaneous 
compounding and should never be dispensed as a dosage form. 
 
(c) Hypodermic tablets 
Hypodermic tablets are soft, readily soluble tablets and originally were used for the 
preparation of solutions to be injected. Since stable parenteral solutions are now 
available for most new drug substances, there is no justification for the hypodermic 
tablets for injection. Their use in this manner should be discouraged, since the 
resulting solutions are not sterile. Large quantities of these tablets continue to be 
made, but for oral administration. No hypodermic tablets ever have been recognized 
by the official compendia 
 
1.4.4 INSERTED TABLETS
(2) 
(a) Dental cones 
These are relatively minor compressed tablets meant for placing them in the empty 
socket-after tooth extraction. They prevent the multiplication of bacteria in the socket 
following such extraction by using slow releasing antibacterial compounds or to 
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reduce bleeding by containing the astringent. These cones generally get dissolved in 
20 to 40 min time. 
 
(b) Implantation tablets 
These tablets are placed under the skin or inserted subcutaneous by means of minor 
surgical operation and are slowly absorbed. These implants must be sterile and should 
be packed individually in sterile condition. Implants are mainly used for 
administration of hormones such as testosterone, and deoxycorticosterone etc. 
 
(c) Vaginal tablets 
These tablets are meant to dissolve slowly in the vaginal cavity. These tablets are 
typically ovoid or pear shaped to facilitate retention in the vagina. This tablet form is 
used to release steroids, antibacterial agents, antiseptics or astringents to treat vaginal 
infections. 
The goal of any drug delivery system is to provide a therapeutic amount of drug in the 
proper site in the body to achieve promptly and then to maintain the desired   drug 
concentration that is, the drug delivery system should delivery system should deliver 
drug at a rate dedicated by the needs of the body over a specified period of treatment. 
 
1.5 ORAL DRUG DELIVERY
(3) 
This is the most widely utilized route of administration among all the routes that have 
been explored for systemic delivery of drugs via pharmaceutical products of different 
dosage form. Oral route is considered most natural, uncomplicated, convenient and 
safe due to its ease of administration, patient acceptance and cost effective 
manufacturing process. 
For many drug substances conventional immediate release formulations provide 
clinically effective therapy while maintaining the required balance of pharmacokinetic 
and pharmacodynamics profiles with an acceptable level of safety to the patient. 
                      Oral drug delivery is the most desirable and preferred method of 
administering therapeutic agents for their systemic effects. In addition, the oral 
medication is generally considered as the first avenue investigated in the discovery 
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and development of new drug entities, pharmaceutical formulations, mainly because 
of patient compliance  and convenience in administration.  
                Oral route of drug administration have wide acceptance up to 50-60% of 
total dosage forms. Solid dosage forms are popular because of ease of administration, 
accurate dosage, self-medication, pain avoidance and most importantly patient 
compliance. The most popular solid dosage forms are tablets and capsules. But the 
important drawback of these dosage forms is the difficulty to swallow.  
                     Oral dosage form is the most popular route for drug therapy. Over 80% 
of the drugs formulated to produce systemic effects in the United States are produced 
as oral dosage forms. Compared to other oral dosage forms, tablets are the 
manufacturer‟s dosage form of choice because of their relatively low cost. 
 
1.5.1 Current technologies in oral drug delivery
(3) 
Over the last 3 decades, many novel oral drug therapeutic systems have been invented 
along with the appreciable development of drug delivery technology. Although these 
advanced DDS are manufactured or fabricated in traditional pharmaceutical 
formulations, such as Tablets, Capsules, Sachets, Suspensions, Emulsions, and 
Solutions, they are superior to the conventional oral dosage forms in terms of their 
therapeutic efficacies, toxicities, and stabilities.  
Based on the desired therapeutic objectives, oral DDS may be assorted into three 
categories:  
• Immediate-release preparations,  
• Controlled-release preparations and        
•     Targeted- release preparations.  
Immediate-Release Preparations
(4) 
These preparations are primarily intended to achieve faster onset of action for drugs 
such as analgesics, antipyretics, and coronary vasodilators. Other advantages include 
enhanced oral bioavailability through transmucosal delivery and pregastricabsorption, 
convenience in drug administration to dysphasic patients, especially the elderly and 
bedridden. 
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        Conventional IR formulations include fast disintegrating tablets and granules 
that use effervescent mixtures, such as sodium carbonate (or sodium bicarbonate) and 
citric acid (or tartaric acid), and superdisintegrants, such as sodium starch glycolate, 
crosscarmellose sodium, and crospovidone. Current technologies in fast-dispersing 
dosage forms include modified tableting systems, floss or Shear form technology, 
which employs application of centrifugal force and controlled temperature, and 
freeze-drying.  
 
Controlled-Release Preparations (CR) 
The currently employed CR technologies for oral drug delivery are diffusion-
controlled systems; solvent activated systems, and chemically controlled systems. 
Diffusion-controlled systems include monolithic and reservoir devices in which 
diffusion of the drug is the rate-limiting step, respectively, through a polymer matrix 
or a polymeric membrane. Solvent-activated systems may be either osmotically 
controlled or controlled by polymer swelling. Chemically controlled systems release 
drugs via polymeric degradation (surface or bulk matrix erosion) or cleavage of drug 
from a polymer chain. It is worth mentioning here that the so-called programmed-
release („„tailored-release‟‟) profile of a final CR product is rarely the outcome of a 
single pharmaceutical principle. Depending on the specific physicochemical 
properties of the drug in question and desired therapeutic objectives, different 
formulation and CR principles may be proportionally combined within the same 
dosage form. This task appears to be simpler when realized in terms of appropriate 
selection of polymers and excipients that incorporate desired principles. 
  
Targeted-Release Preparations 
Site-specific oral drug delivery requires spatial placement of a drug delivery device at 
a desired site within theGgastro Intestinal (GI) tract. Although it is virtually possible 
to localize a device within each part of GI tract, the attainment of site-specific 
delivery in the oral cavity and the rectum is relatively easier than in the stomach and 
the small and large intestines. The latter requires consideration of both longitudinal 
and transverse aspects of GI constraints.  
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1.6 MANUFACTURING METHODS
(2,5) 
There are four general methods of tablet preparation. 
 Direct compression                                                                                                                             
 Wet granulation method 
 Dry granulation method 
 Fluidized bed granulation 
In the tablet-pressing process, it is important that all ingredients be dry, powdered, 
and of uniform grain size as much as possible. The main guideline in manufacture is 
to ensure that the appropriate amount of active ingredient is equal in each tablet so 
ingredients should be well-mixed. Compressed tablets are exerted to great pressure in 
order to compact the material. If a sufficiently homogenous mix of the components 
cannot be obtained with simple mixing, the ingredients must be granulated prior to 
compression to assure an even distribution of the active compound in the final tablet. 
Two basic techniques are used to prepare powders for granulation into a tablet: wet 
granulation and dry granulation.Powders that can be mixed well do not require 
granulation and can be compressed into tablets through Direct Compression.  
 
Direct Compression 
This method is used when a group of ingredients can be blended and placed in a tablet 
press to make a tablet without any of the ingredients having to be changed. This is not 
very common because many tablets have active pharmaceutical ingredients which will 
not allow for direct compression due to their concentration or the excipients used in 
formulation are not conducive to direct compression. 
Granulation is the process of collecting particles together by creating bonds between 
them. There are several different methods of granulation. The most popular, which is 
used by over 70% of formulation in tablet manufacture is wet granulation. Dry 
granulation is another method used to form granules. 
 
Wet granulation 
Wet granulation is a process of using a liquid binder or adhesive to the powder 
mixture. The amount of liquid can be properly managed, and over wetting will cause 
the granules to be too hard and under wetting will cause them to be too soft and 
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friable. Aqueous solutions have the advantage of being safer to deal with than 
solvents. 
 Procedure of Wet Granulation  
 Step 1: Weighing and Blending - the active ingredient, filler, disintegration 
agents, are weighed and mixed. 
 Step 2: The wet granulate is prepared by adding the liquid binder/adhesive. 
Examples of binders/adhesives include aqueous preparations of cornstarch, 
natural gums such as acacia and cellulose derivatives such as methyl 
cellulose, CMC, gelatin, and povidone. Ingredients are placed within a 
granulator which helps ensure correct density of the composition. 
 Step 3: Screening the damp mass into pellets or granules 
 Step 4: Drying the granulation 
 Step 5: Dry screening: After the granules are dried, pass through a screen 
of smaller size than the one used for the wet mass to select granules of 
uniform size to allow even fill in the die cavity 
 Step 6: Lubrication- A dry lubricant, antiadherent and glidant are added to 
the granules either by dusting over the spread-out granules or by blending 
with the granules. Its reduces friction between the tablet and the walls of 
the die cavity. Antiadherent reduces sticking of the tablet to the die and 
punch. 
 Step7: liquid binder, but sometimes many actives are not compatible with 
water. Water mixed into the powder can form bonds between powder 
particles that are strong enough to lock them in together. However, once 
the water dries, the powders may fall apart and therefore might not be 
strong enough to create and hold a bond.  
 
Dry granulation 
This process is used when the product needed to be granulated may be sensitive to 
moisture and heat. Dry granulation can be conducted on a press using slugging tooling 
or on a roller compactor commonly referred to as a chilsonator. Dry granulation 
equipment offers a wide range of pressure and roll types to attain proper densification. 
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However, the process may require repeated compaction steps to attain the proper 
granule end point. It requires drugs or excipients with cohesive properties. 
 Some granular chemicals are suitable for direct compression (free flowing) 
e.g. potassium chloride. 
 Tableting excipients with good flow characteristics and compressibility allow 
for direct compression of a variety of drugs. 
 
Fluidized bed granulation 
It is a multiple step process performed in the same vessel to pre-heat, granulate and 
dry the powders. It is today a commonly used method in pharmaceuticals because it 
allows the individual company to more fully controls the powder preparation process. 
It requires only one piece of machinery that mixes all the powders and granules on a 
bed of air. 
 
1.7 EXCIPIENTS USED IN TABLETS
(6) 
Excipients are inert substances used as diluents or vehicles for a drug. In the 
pharmaceutical industry it is a catch all terms which includes various sub- groups. 
Comprising diluents or fillers, binders or adhesives, disintegrants, lubricants, glidants 
or flavours, fragrances and sweeteners. All of these must meet certain criteria as 
follows:- 
 They must be physiological inert. 
 They must be acceptable to regulatory agencies 
 They must be physiologically and chemically stable. 
 They must be free of any bacteria considered to be pathogenic or otherwise    
objectionable. 
 They must be not interfere with the bioavailability of the drug. 
 They must be commercially available in the form and purity commensurate to 
pharmaceutical standards. 
 Cost must be relatively inexpensive. 
 
                       To assure that no excipient interferences with the utilization of the 
drug, the formulator must carefully and critically evaluate combinations of the drug 
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with each of the contemplated excipients and must ascertain compliance of each 
ingredient with existing standards and regulations. 
 The screening of drug-excipients and excipient-excipient interactions should be 
carried out routinely in preformulations studies.  
 
Fillers (Diluents) 
Tablet fillers of comprise a heterogeneous group of substances. Since they often 
comprise the bulk of the tablet, selection of a candidate from this group as a carrier 
for a drug is of prime importance.  
 
Binders 
Binders are the glue that holds powders together to form granules. They are the 
adhesives that are added to tablet formulations to provide the cohesiveness required 
for that bonding together of the granules under compaction to form a tablet. The 
quantity used and the method of application must be carefully regulated, since the 
tablet must remain intact when swallowed and then release its medicament. 
 
Lubricants 
Lubricants are used in tablet formulation to ease the ejection of the tablet from the die, 
to prevent sticking of tablets to the punches, and to prevent excessive wear on 
punches and dies. They function by interposing a film of low shear strength at the 
interface between the tablet and the die wall and the punch face.         
In selecting a lubricant, the following should be considered: 
 Lubricants markedly reduce the bonding properties of many excipients.  
 Over blending is one of the main causes of lubrication problems. Lubricants 
should be added last to the granulation and tumble-blended for not more than 
10 min. 
 Lubricant efficiency is a function of particle size; therefore, the finest grade 
available should be used and screened through a 100-300 mesh screen before 
use. 
 Examples of lubricants commonly used are magnesium stearali acid, talc, 
starch. 
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Disintegrants 
Disintegrants are used in tablet preparation to break the tablet faster. But some of the 
disintegrants are also having property of enhancing solubility of insoluble drug. 
Examples 
 Crospovidone: Crospovidone is disintegrant, crospovidone also enhances 
solubility. 
 Sodium starch glycollate: sodium starch glycollate is widely used in oral 
pharmaceuticals and as a disintegrant in capsule. 
 
Glidants 
Glidants are materials that improve the flow characteristics of granules by reducing 
the inter particulate friction. In proper amounts they also serve to assure smooth and 
uniform flow at all times.  
                      Many of the excipients commonly used in tablet formulations are 
especially applicable for use in chewable tablets due to their ability to provide the 
necessary properties of sweetness and chewabilty. In general; these fall into the sugar 
category, although a combination of excipients with artificial sweeteners may provide 
a satisfactory alternative. 
 
MISCELLANEOUS 
Wetting Agents 
Wetting Agents in tablet formulation aid water uptake and thereby enhancing 
disintegration and assisting in drug dissolution. Incorporation of anionic surfactant 
like Sodium Lauryl Sulphate (SLS) is known to enchance the dissolution. It has been 
established that SLS improves permeation of drug biological membrane since it 
destroys the path through which drug has to pass and thus minimizing the path length 
for the drug to travel. Wetting agents are mainly added when hydrophobic drug is to 
be formulated into tablet. SLS, Sodium disobutylsulfosuccinate are used as wetting 
agent in tablet formulation. 
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Dissolution Retardants 
Dissolution Retardants are incorporated into tablet formulation only when controlled 
release of drug is required. Waxy materials like stearic acid and their esters can be 
used as dissolution retardants. 
 
Dissolution Enhancers 
They are the agents that alter the molecular forces between ingredients to enchance 
the dissolution of solute in the solvent. Fructose, Povidone, Surfactants are used as 
dissolution enhancer. 
 
Adsorbents 
Adsorbents are the agents that can retain large quantities of liquids. Therefore liquids 
like Vitamin E can be incorporated into tablets by addition of adsorbents. Most 
commonly used adsorbents in pharmaceuticals are anhydrous calicium phosphate, 
starch, magnesium carbonate, bentonite, kaoline, magnesium oxide. Generally the 
liquid to be adsorbed is first mixed with the adsorbent prior to incorporation into the 
formulation. 
 
Buffers 
Buffers are added to maintain a required pH since a change in pH may cause 
significant alteration in stability. Most commonly used buffering agent in tablet 
formulation includes sodium bicarbonate, calcium carbonate, and sodium citrate. 
 
Antioxidants 
Antioxidants are added in tablet formulation to protect drug from undergoing 
oxidation. Antioxidants undergo oxidation in place of drug or they block the oxidation 
reaction or they act as synergisys to other antioxidants. 
 
Chelating Agents 
Chelating agents tend to form complexes with trace amount of heavy metals ions 
inactivating their catalytic activity in the oxidation of medicaments. 
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Ethlenediaminetetracetic acid and its salts, Dihydroxy Ethyl Glycerin, Citric Acid and 
Tartaric Acid are most commonly used chelators 
 
Flavors 
Flavours are added to tablet formulation in order to make them enough in case of 
chewable tablet by improving the taste. Flavours are commonly used to improve the 
taste of chewable tablets as well as mouth dissolved tablets. Flavours are incorporated 
either as solids (spray dried flavours) or oils or aqueous (water soluble) flavors. 
 
Sweeteners 
Sweeteners are added to tablet formulation to improve the taste of chewable tablets. 
Sweeteners used in tablet formulation- Mannitol, Lactose, Sucrose, Dextrose, 
Saccharin, Cyclamate, Aspartame etc.       
 
1.8 TABLET COATING
(7,8) 
Coated tablets are defined as the covered with one/more layers of mixtures of various 
substances such as natural waxes authorized colouring materials. coating may also 
contain active ingredient. Substances used for coating are usually applied as 
solution/suspension under condition where vehicle evaporates. 
 
Why Tablet Coating is required?  
A number of reasons can be suggested:  
  The core contains a material which has a bitter taste in the mouth or 
has an unpleasant odour.  
  Coating will protect the drug from the surroundings with a view to 
improve its stability.  
  Coating will increase the ease by which a tablet can be ingested by the 
patient.  
  Coating will develop the mechanical integrity; means coated products 
are more        
resistant to mishandling (abrasion, attrition etc.)  
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  The core contains a substance which is incompatible in the presence of 
light and  
subject to atmospheric oxidation, i.e. a coating is added to improve 
stability.  
  The core alone is inelegant.  
  The active substance is coloured and migrates easily to stain hands 
and clothes.  
  The coated tablets are packed on high-speed packaging machine. 
Coating reduces  
friction and increases packaging rate.  
  Coating can modify the drug release profile, e.g., enteric coating, 
osmotic pump,  
pulsatile delivery. 
 
1.8.1 Types of coating
(7,8) 
 Sugar coating 
 Film coating 
 Enteric coating  
 Controlled release coating 
 Specialized coating 
 Compressed coating 
 Electrostatic coating 
 Dip coating 
 Vacuum film coating 
 
1.8.2 FILM COATING
(7,8) 
Film coating is the process whereby a tablet, capsule, or pellet is surrounded by a thin 
layer of polymeric material.Film coated tablets are compressed tablets with a thin 
layer of suitable polymer capable of forming a skin like film over the tablet. The 
polymeric substance most commonly used are hydroxyl propyl methyl cellulose, 
hydroxyl methyl cellulose, The film is usually colored and has the advantage over 
sugar coating in that it is more durable, less bulky, and less time consuming to apply. 
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The film coating protects the medicament from the atmospheric effects. By its 
composition the coating is designed to rupture & expose the core tablet at the desired 
location with in GIT. 
                          Table-1Reasons for Filmcoating 
Reasons for film coating include 
Appearance 
To change the color, for branding purposes or other aesthetic 
reasons 
Stability 
To protect the active ingredient from moisture, light, and/or the 
acidic environment of the stomach 
Taste/odor  Masking 
To provide an easy to swallow tablet without the bitter taste of 
many actives 
Release 
characteristics 
Many film coating materials have functional properties which 
enable the delayed (enteric) release of dosage forms 
 
Process Description 
Film coating is a deposition of a thin layer of polymer surrounding the tablet core 
.Conventional pan equipments may be used but now a days more sophisticated 
equipments are employed to have high degree of automation of coating time. The 
polymer is solubilized into solvent, other additives like plasticizer &pigments are 
added. Resulting solution is sprayed on to a rotated tablet bed. The drying conditions 
cause removal of the solvent, giving thin deposition material around each tablet core. 
 
Process Details 
Usually spray process is employed in preparation of film coated tablet. Accelacota is 
the type of prototype of perforated cylindrical drum providing drying air capacity. 
Fluidized bed equipment has made considerable impact where tablets are moving in a 
stream of air passing through the perforated bottom of a cylindrical column with a 
smaller cylindrical insert the stream of cores is rising in the centre of device together 
with spray mist applied in the middle of the bottom. For fluidized coating very hard 
tablet hardness above 20 N have to be used. 
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Materials used in film coating 
 Opaquent extenders 
 Miscellaneous coating solution components 
 
Examples of film formers 
Hydroxyl propyl methyl cellulose (HPMC),Methyl hydroxyl ethyl cellulose 
(MHEC),Ethyl cellulose (EC),Hydroxyl propyl cellulose (HPC), sodium carboxyl 
methyl cellulose (CMC), Acrylate polymers, Povidone. 
Advantages 
    It is less time consuming technology. 
    Not much labour is required. 
    No adverse effect on Disintegration time of tablet. 
    Production cost is low because material used for coating is cheap. 
    Protects drug from atmospheric changes such as light, air, moist. 
 
1.8.3 Immediate Release Film Coating Systems for Tablets
(9,10,11) 
Colorcon, the innovator and industry standard for complete film coating systems, 
offers a range of custom pigmented and non-pigmented film coatings for immediate 
release solid dose applications. film coating formulas produce attractive, elegant 
coatings on even the most challenging tablet surfaces and can be used in both aqueous 
and organic coating procedures. 
An extensive selection of polymer blend formulations provides the user with the 
ability to impart  
      many beneficial features to a solid oral dosage formulation. Benefits include: 
• Reduced coating process time  
• Superior adhesion on difficult to coat cores  
• Less stressful processing conditions for heat sensitive, friable or high drug  
contentcores 
• Sharper logo definition, even at higher weight gains  
• Better gloss and smoothness compared to conventional film coatings  
• Improvedcolor stability  
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                             Aqueous film coating is the quickest and least expensive method for 
enhancing your tablet appearance and, unlike other methods, will not affect 
dissolution or disintegration profiles. dry-blend systems consist of polymers, 
plasticizers and pigments, combined in one, easy-to-use, dry powder system which is 
rehydrated quickly and simply with water. Colorcon also offers customized colour 
selection and colour matching of our immediate release tablet film coating products.  
Celeron‟s ongoing research of film coating polymers has produced many enhanced 
polymer combinations resulting in new tablet coating options for our customers. Our 
newly developed, dry coating technology provides benefits such as improved 
adhesion, reduced processing times, and application of the tablet coating at wider 
process parameters. Advances in our immediate release tablet film coating technology 
not only give a more elegant appearance to your solid oral dosage form, but provide 
unique.  
Figure-1 Film coating Tablets 
 
 
 
 
 
 
  
 
 
 
 
1.8.4 Film Coatings for Every Application
(9,10)
 
Colorcon offers a wide range of film coating products, many of which can be 
formulated specifically for your application and regulatory requirements. Whether the 
desired function for your tablet or particulate is immediate release, delayed (enteric) 
release and/or extended (controlled) release,  the tablet film coating technology 
needed to enhance, protect, and modify the functionality of  product. 
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Immediate Release 
A distinctive product appearance offers many benefits to the producers and marketers 
of pharmaceutical tablets and nutritional supplements. Film coating is the most 
economical method of enhancing your product – improving visual appearance, as well 
as easing swallow ability, and enhancing the taste and masking objectionable odors. 
Colorcon film coatings can impart mechanical integrity, color, gloss, pearlescence or 
moisture protection to create an immediate release tablet that is both memorable and 
effective. 
 
Extended Release  
The extensively used polymer for extended release coating was Ethyl cellulose. 
Application of an ethyl cellulose film from aqueous dispersion or organic solution 
provides the formulator the means to control the release of drug from a tablet or 
multiparticulatevia diffusion of the drug through the ethyl cellulose film. Novel means 
of controlled release can also be achieved using a combination of Colorcon's modified 
release coating systems. 
 
Delayed Release 
The enteric/delayed release products can help the deliver of final product that saves 
you development, scale-up and production time while assuring the integrity of the 
coating for the safety and efficacy of your finished dosage form. Various systems are 
available based on a variety of delayed release polymers for aqueous or organic 
processing to provide targeted release at various pH conditions.  
                         For the solid dosage manufacturer, tablet film coating technology 
conveys many benefits including improved packaging efficiency, prevention of cross 
contamination and reduced tablet breakage and chipping. A large variety of 
pigmented and non-pigmented tablet film coating systems available. Which is cost 
Effective, protect from light moisture and environmental gases. 
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1.9 IMMEDIATE RELEASE DRUG DELIVERY SYSTEM
(9,10,11) 
Immediate release drug delivery system is a conventional type of drug delivery. It is 
designed to disintegrate and release their medicaments with no special rate controlling 
features.
 
These are the dosage forms in which ≥ 85% of labelled amount dissolves with in 30 
min. However for immediate release tablets, tablet disintegrants play an important 
role in ensuring that the tablet matrix break up on contact with fluid in the stomach to 
allow the release the active drug which then become available in whole or in part, for 
absorption from gastrointestinal tract. 
 
1.9.1 Mechanism of drug release
(10,11) 
On exposure to aqueous fluids, hydrophilic matrices take up water and the polymer 
starts hydrating to form a gel layer. Drug release is controlled by diffusion barriers/ by 
surface erosions. An initial burst of soluble drug may occur due to surface leaching  
when a matrix containing a swellable glassy polymer comes in to contact with an 
aqueous medium, there is an abrupt change from a glassy to rubbery state associate 
with swelling process with time, water infiltration deep in to a case increasing the 
thickness by the gel layer. The outer layer becomes fully hydrated and starts 
dissolving or eroding. When water reaches the center of the system and the 
concentration of drug falls below the solubility value, the release rate of the drug 
begins to reduce. At the same time an increase in thickness of the barrier layer with 
time increases the diffusion path length, reducing the rate of drug release.  
 
1.9.2 Advantages of immediate release drug delivery system 
 Release the drug immediately. 
 More flexibility in adjusting the dose. 
 It can be prepared with minimum dose of drug. 
 There is no dose dumping problem 
 Immediate release drug delivery systems can be 
used in both  
initial stage and final stage of disease. 
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1.9.3 Super disintegrants in immediate release 
These are especially important for an immediate release product where rapid release of 
dug substance is required. A disintegrant can be added to powder blend for direct 
compression.  
                           Table-2 Super Disintegrants 
 
1.9.4 MECHANISM OF TABLET DISINTEGRATION
(12) 
Disintegrants, an important excipient of the tablet formulation, are always added to 
tablet to induce breakup of tablet when it comes in contact with aqueous fluid and this 
process of disintegration of constituent particles before the drug dissolution occurs, is 
known as disintegration process and excipients which induce this process are known 
as disintegrants. 
The tablet breaks to primary particles by one or more of the mechanisms: 
 capillary action (Wicking) 
 swelling 
 Due to deformation 
 Due to release of gases 
 
Super 
disintegrants 
Example Mechanism of action Special comment 
Crosscarmellose 
 
Crosslinked 
Cellulose 
-Swells 4-8 folds in < 10 
seconds. 
-Swelling and wicking 
both. 
-Swells in two 
dimensions. 
-Direct compression 
or granulation 
Crosspovidone 
 
Crosslinked 
PVP 
-Swells very little and 
returns to original size after 
compression but act by 
capillary action 
-Water insoluble 
and 
spongy in nature so 
get 
porous tablet 
Pre Gelatinized 
Starch 
Starch 
1500 
-Swells 7-12 folds 
in < 30 seconds 
-Swells in three 
dimensions and 
high 
level serve as 
sustain 
release matrix 
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Capillary action (Wicking) 
Effective disintegrants that do not swell are believed to impart their disintegrating 
action through porosity and capillary action. Tablet porosity provides way for the 
penetration of fluid into tablets. The disintegrant particles (with cohesiveness and 
compressibility) themselves act to enhance porosity and provide these capillaries into 
the tablet. Liquid is drawn up or leak into these ways by capillary action and rupture 
the inter-particulate bonds causing the tablet to break into small particles 
 
Swelling 
Not all disintegrants swell in contact with water swelling is believed to be a 
mechanism in which; certain disintegrating agents (like starch) impart their 
disintegrating effect. By swelling on contact with water the adhesiveness of other 
ingredients in a tablet is overcome causing the tablet to disintegrate. 
 
Figure-2 Mechanism Of Disintegration By Wiciking and Swelling 
                     
  
 
 
 
 
Particles swell and break up the matrix 
from within; swelling sets up; localized 
stress spreads throughout the matrix. 
Water is pulled into pores by disintegrants 
and reduces the physical bonding between 
particles. 
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Deformation. 
Starch grains are generally thought to be “elastic” in nature that is the grains that are 
deformed under pressure will return to their original shape when that pressure is 
removed. But, with the compression force involved in tabletting, these grains are 
permanently deformed and are said to be “Energy Rich” with these energy being 
released upon exposure to water, i.e. the ability for starch to swell is higher in 
“Energy Rich starch” grains than in starch grains that have not been deformed under 
pressure. It is believed that no single mechanism is responsible for the action ofmost 
disintegrants. But rather, it is more likely the result of inter-relationships between 
these major mechanisms 
 
Figure-3   Mechanism of tablet disintegration by deformation 
 
  Particles swell to precompression size and break up the matrix 
 
Release of gases 
Carbon dioxide released within tablets on wetting due to interaction between 
bicarbonate and carbonate with citric acid or tartaric acid. The tablet disintegrates due 
to generation of pressure within the tablet. This effervescent mixture is used when we 
needs to formulate very rapidly dissolving tablets or fast disintegrating tablet.       
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1.10 INTRODUCTION TO AIDS/HIV
(13,14,15,16,17)
 
The virus infects the lymphocytes, the brain cells and macrophages. The illness is due 
to a single defect, viz destruction of the helper T lymphocytes (CD4) by the 
replicating virus particles, and impairment offunctioning of the surviving CD4  cells. 
The patient therefore suffers from a specific defect in the cellular arm of the immune 
system. Cardiovascular and kidney has been reported. 
The incubation period is estimated to be 1 to 7 years (means 4.5 years) Antibodies to 
HIV develop in 2-8 weeks after infection. 
 
1.10.1Treatment 
Current treatment for HIV infection of highly active antiretroviral therapy, or 
HAART. This has been highly beneficial to many HIV-infected individuals since its 
introduction in 1996, when the protease inhibitor-based HAART initially became 
available. Typically, these classes are two nucleoside analogue reverse transcriptase 
inhibitors (NARTIs or NNRTI).  
 
1.10.2Classification of Drugs
(14,17,18,19) 
        Drugs used against the retrovirus in AIDS 
1. Nucleoside and Nucleotide reverse transcriptase inhibitors(NRTI) 
2. Non- Nucleoside reverse transcriptase inhibitors(NNRTI) 
3. Protease inhibitors 
4. Integrase inhibitors 
5. Viral entry inhibitors 
6. Viral assembly inhibitors 
 
1) Nucleoside and Nucleotide reverse transcriptase inhibitors(NRTI) 
Their intended therapeutic action is to prevent the formation of HIV DNA by 
inhibiting HIV reverse transcriptase. Ex: Zidovudine, Stavudine, Didanosine, 
Zalcitabine, Abacavir, Emtricitabine and Azidothymidine (nucleosides) and Tenofovir 
(nucleotide). 
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2) Non- Nucleoside reverse transcriptase inhibitors (NNRTI) 
Unlike the nucleoside analogs, the NNRTIs interfere with HIV-1 reverse transcriptase 
by noncompetitively binding directly to the enzyme downstream from the active 
catalytic site. Ex: Nevirapine, Efavirenz and Delaviridine. 
 
3) Protease inhibitors 
This protease cleaves multidomain viral proteins into their active forms; blocking this 
process completely would prevent the virus from being infectious. Ex: saquinavir, 
Ritonavir, Indinavir, Nefinavir and Lopinavir. 
 
4)Integrase inhibitors 
Multiple steps in the integration process are catalyzed by HIV-1 integrase. The 
integration of HIV-1 DNA into the host chromosome is achieved by the integrase 
performing a series of cutting and joining reactions. Integrase inhibitors seek to block 
the integrase enzyme from allowing this integration process from happening. Ex: 
Raltegravir 
 
5) Viral entry inhibitors 
An infectious HIV-1 virion consists of a nucleoprotein core surrounded by a lipid 
bilayer membrane derived from the cell that produced the virion. The virus membrane 
and plasma membrane of the host cell represent physical barriers between the core 
and its destination. To breach these barriers, enveloped viruses have evolved genes 
encoding proteins that catalyze the fusion of viral and cellular membranes and thereby 
place the core in the host cell cytoplasm. Ex: Enfuvirtide. 
 
6) Viral assembly inhibitors 
Assembly and release of HIV-1 are governed by the viral gag and vpu proteins. 
Following its synthesis in the cytosol, gag is rapidly and specifically transported to the 
site of virus assembly. The goal of these inhibitors is to block assembly or release by 
binding to one of these components. 
 
 
40 
 
2. AIM AND OBJECTIVE 
 
      AIM 
 The aim of present work is to formulate film coated tablets of Emtricitabine 
combination with Tenofovir disoproxil fumaratetablets comparable to the 
marketed product. 
 
OBJECTIVE 
 To develop a pharmaceutically stable, cost effective and quality improved 
formulation of Emtricitabine combination with Tenofovir disoproxil fumarate 
tablets.  
 To study the release profile of the dosage form and to compare their drug-
release profiles with the innovator. 
 To determine the best fit dissolution profile for dosage form.  
 To study the stability of dosage form and compare with  the specification . 
 The physical parameters evaluation, in-vitrodrug release studies and stability 
studies are conducted to justify the formulation efficacy. 
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3. LITERATURE SURVEY 
 
1.Takuma Shirasaka.,et al.,(2011) studied the the incidence of FTC-associated SP in 
Japanese patients was 3.9%, and was comparable to the previously reported incidence 
in Asian patients (4%). FTC-associated SP was not associated with any clinically 
significant symptoms and has little clinical significance.
 (20) 
 
2.DanielDrogan.,et al.,(2010)Studied the suppression of drug-sensitive viruses is 
significantly enhanced by FTC compared to 3TC. Mathematical modeling of the 
distinct rates of suppression of drug-sensitive viruses revealed an approximately 3-
fold higher antiretroviral potency for FTC compared to 3TC.
 (21) 
 
3. Alessandro Soria.,et al.,(2010) Studied that Once-weekly emtricitabine led to a 
higher viral rebound than once-daily monotherapy, but similar immunological 
changes, thus  suggesting a role  of M184V in slowing the decrease in CD4% in 
treatment failing subjects.
 (22) 
 
4.Abhay Gupta.,et al.,(2009) the correlation between disintegration and dissolution 
for immediate release tablets containing a high solubility drug and to identify 
formulations where disintegration test, instead of the dissolution test, may be used as 
the acceptance criteria based on International Conference on Harmonization  
guidelines.
 (9)
 
 
5. Julia Krause.,et.al.,(2009) Studied The preparation ofimmediate release pellets 
with solid lipid binders through a solvent-free cold extrusion/spheronisation process 
was investigated in this study pellets showed favourable properties like spherical 
shape, narrow size distribution, a high drug load of 80% sodium benzoate and a 
drugrelease of more than 90% within 40 min..
 (23) 
 
6.LaurenceBousquet.,et al.,(2008) studied Emtricitabine has both inhibitor and 
substrate characteristics with MRP1 in PBMCs in vitro, and does not interact with PI 
accumulation.
 (24) 
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7.Chee-Kin Hui.,et al.,(2008)Combination ADV plus FTC resulted in more potent 
suppression of HBV DNA over 96 weeks of therapy.
 (25)
 
 
8.Jessica Tan.,et al.,(2008) Discussed thatTDF monotherapy is effective for patients 
with virologic breakthrough or suboptimal response to ADV, but combination therapy 
with a nucleoside analogue should be considered in patients with ADV-resistance.
 (26) 
 
9.Giordano Madeddu,,et al.,(2008) studied Both prevalence and incidence of   
nephrotoxicity were low in patients receivingtenofovir in a non-selected clinical 
setting. Renal injury in patients receivingtenofovir seems associated with the presence 
of co-morbidities and with advanced HIV infection
 (27) 
 
10.Giuseppe Gumina., et al.,(2007) told thatCurrently, two L-nucleosides, 
lamivudine and emtricitabine, are available for the treatment of human 
immunodeficiency virus and hepatitis B virus infections, and several other analogs, 
such as clevudine and troxacitabine, are in advanced clinical trial development stages.
 
(28)
 
 
11. Sabah Souliman.,et al.,(2006) Investigated to USP II method, the novel in vitro 
model demonstrated a high level of efficacy in mimicking the behaviour of 
acetaminophen IR tablets  in vivo in fasted and fed states.
 (10) 
 
12. Gail Skowronet.,et al.,(2006)demonstrate the Short-term monotherapy studies 
have demonstrated that emtricitabine 200 mg QD reduces HIV RNA levels by 1.7 to 
1.92 log10 copies/mL. Current US DHHS and IAS-USA guidelines support 
emtricitabine as a recommended component of an initial antiretroviral regimen
 (18) 
 
13. Robert G. Gish.,et al.,(2005) discussed that Emtricitabine was well tolerated and 
demonstrated a potent antiviral response for up to 2 years in patients with chronic 
hepatitis B infection. Based on these data, 200 mg emtricitabine once daily was 
chosen as the optimal dose for future  hepatitis B studies.
 (11) 
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14. Tomas Cihlar.,et al.,(2005) studied tenofovir exhibited weak cytotoxic effects in 
all cell types tested with less in vitro cytotoxicity than the majority of NRTIs currently 
used for the treatment of HIV disease.
 (29) 
 
15. George M. Szczech.,et al.,(2003)Reproductive and developmental toxicology 
studies were conducted with emtricitabine, a nucleoside analog in development for 
treatment of  human immunodeficiency virus (HIV) (Phase III) and hepatitisB(HBV) 
(Phase III) infections. The development and fertility of F1 progeny were unaffected 
by emtricitabine in a mouse pre- and post-natal study. These data demonstrate a 
favorable pre-clinicalreproductive safety profile for emtricitabine.
 (30)
 
 
16. Horatio B. Fung.,et al.,(2002) studied tenofovir DF has exhibited anti-HIV 
activity invarious HIV-infected cell lines and has produced a synergistic or additive 
effect against HIV when combined with other antiretroviral agents, tenofovir DF 
appears to be a promising agent for the treatment of HIV infection.
 (19) 
 
17. Montaner.J.S.G.,et al.,(1999) Currently available antiretrovirals require 
combination therapy with at least three agents to achieve the goal of suppressing viral 
replication to as low as possible.
 (16)
 
 
18.Komal F. Chopra.,et al.,(1997) investigated that Early initiation of treatment with 
multidrug therapy in all individuals infected with HIV is recommended by most 
experts with the common goal of reducing, viral load to a nondetectable level. 
Numerous studies have shown the increased efficacy of multidrug therapy over 
monotherapy.
(17) 
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4. PLAN OF WORK 
Process Flow Chart 
 
Preformulation studies for the API. 
 
Compatibility studies of API and excipients 
 
Optimisation of concentration of excipients and method of manufacture 
 
Pre compression studies for granules/blend 
 
Preparation of stable Emtricitabine and Tenofovir disoproxil fumarate tablets 
 
Coating of the core Tablets 
 
Evaluation of physical parameters like diameter, thickness, hardness, 
friability and disintegration time of tablets 
 
Evaluation of in-vitrodrug release profiles for the tablets 
 
Comparative studies of Emtricitabine and Tenofovir disoproxil fumarate   tablets 
with innovator 
 
Compilation of stability data by accelerated stability studies. 
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5. DRUG PROFILE 
 
5.1 Emtricitabine
(11,31,32,33)
 
Chemical Name [IUPAC Name] 
The chemical name is 4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-
oxathiolan-5-yl]-1,2-dihydropyrimidin-2-one 
 
Molecular Formula 
The empirical formula of Emtricitabine is  C8 H10 F N3 O3 S 
 
Molecular Weight 
The molecular weight is 247.248 
 
Structural Formula 
 
 
PHYSICOCHEMICAL PROPERTIES 
Colour  :It isawhite to off-white powder. 
Solubility  :Emtricitabine has is a solubility of approximately 112    
                                      mg/mL in water 25 ° C. 
Classification Code : Anti-Infective Agents; Antiretroviral ; Antiviral Agents ;  
                                       Antiviral[treatment of HIV-1 and hepatitis B infections]  
pKa    :2.65 
Meltingpoint   :136-140°C  
PolarSurfaceArea  :79.67 Å
2
  
IndexofRefraction  :1.731  
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MolarRefractivity  :54.01cm
3
  
MolarVolume  :135.1cm
3
  
SurfaceTension  :72.8yne/cm  
Density   :1.82g/cm
3
  
FlashPoint   :221.9°C  
EnthalpyofVaporization :80.89kJ/mol  
BoilingPoint   :443.3°Cat760mmHg  
Vapour Pressure  : 1.01E-09 mmHg at 25°C 
 
DOSAGE AND ADMINISTRATION
 
Recommended Dose 
Emtricitabine may be taken without regard to food. 
 
Adult Patients (18 years of age and older) 
 Emtricitabine capsules: one 200 mg capsule administered once daily orally. 
 Emtricitabine oral solution: 240 mg (24 mL) administered once daily orally. 
 
INTERACTIONS 
Emtricitabine is indicated in combination with other antiretroviral agents for the 
treatment of HIV-1 infection. Additional important information regarding the use of 
Emtricitabine for the treatment of HIV-1 Infection: 
 
Dosage Forms And Strengths 
 Emtricitabine is available as capsules and oral solution. 
 Emtricitabine capsules, containing 200 mg of emtricitabine. 
  Emtricitabine oral solution is a clear, orange to dark orange liquid containing 
10 mg of emtricitabine per mL. 
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MICROBIOLOGY 
Mechanism of Action 
Emtricitabine, a synthetic nucleoside analog of cytidine, is phosphorylated by cellular 
enzymes to form emtricitabine 5'-triphosphate. Emtricitabine 5'-triphosphate inhibits 
the activity of the HIV-1 reverse transcriptase by competing with the natural substrate 
deoxycytidine 5'-triphosphate and by being incorporated into nascent viralDNA which 
results in chain termination.. 
 
Antiviral Activity 
The antiviral activity in cell culture of emtricitabine against laboratory and clinical 
isolates of HIV-1 was assessed in lymphoblastoid cell lines, the MAGI-CCR5 cell 
line, and peripheral blood mononuclear cells. The 50% effective concentration (EC50) 
value for emtricitabine was in the range of 0.0013-0.64 µM (0.0003-0.158 µg/mL).  
 
Resistance 
Emtricitabine-resistant isolates of HIV-1 have been selected in cell culture and in 
vivo. Genotypic analysis of these isolates showed that the reduced susceptibility to 
emtricitabine was associated with a substitution in the HIV-1 reverse transcriptase 
gene at codon 184 which resulted in an amino acid substitution of methionine by 
valine or isoleucine (M184V/I). 
 
CLINICAL PHARMACOLOGY 
Mechanism of Action 
Emtricitabine is an antiviral drug. 
 
Pharmacokinetics 
Absorption 
Emtricitabine is rapidly and extensively absorbed following oral administration with 
peak plasma concentrations occurring at 1-2 hours post-dose. The mean steady state 
plasma trough concentration at 24 hours post-dose was 0.09 µg/mL. 
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Distribution 
In vitro binding of emtricitabine to human plasma proteins was < 4% and independent 
of concentration over the range of 0.02-200 µg/mL. At peak plasma concentration, the 
mean plasma to blood drug concentration ratio was ~1.0 and the mean semen to 
plasma drug concentration ratio was ~4.0. 
 
Metabolism 
In vitro studies indicate that emtricitabine is not an inhibitor of human CYP450 
enzymes. Following administration of 
14
C-emtricitabine, complete recovery of the 
dose was achieved in urine (~86%) and feces (~14%). Thirteen percent (13%) of the 
dose was recovered in urine as three putative metabolites. The biotransformation of 
emtricitabine includes oxidation of the thiol moiety to form the 3'-sulfoxide 
diastereomers (~9% of dose) and conjugation with glucuronic acid to form 2'-O-
glucuronide (~4% of dose). No other metabolites were identifiable. 
 
Elimination 
The plasma half-life of emtricitabine is approximately 10 hours. The renal clearance 
of emtricitabine is greater than the estimated creatinine clearance, suggesting 
elimination by both glomerular filtration and active tubular secretion. There may be 
competition for elimination with other compounds that are also renally eliminated. 
 
DRUGINTERACTIONS 
The potential for drug interactions with EMTRIVA has been studied in combination 
with zidovudine, indinavir, stavudine, famciclovir, and tenofovir disoproxil fumarate. 
There were no clinically significant drug interactions for any of these drugs. 
The following are  adverse reactions: 
 Lactic acidosis/severe hepatomegaly with steatosis 
 Severe acute exacerbations of Hepatitis B 
 Immune reconstitution syndrome. 
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5.2TENOFOVIR DISOPROXIL FUMARATE
((31,33,34,35)
 
Chemical Name [IUPAC Name] 
The chemical name is ({[(2R)-1-(6-amino-9H-purin-9-yl)propan-2-yl]oxy} methyl) 
phos phonic acid. 
 
Molecular Formula 
The empirical formula of Tenofovir disoproxil fumarate is  C19H30N5O10P • C4H4O4 
 
Molecular Weight 
The molecular weight is 635.52 
 
Structural Formula 
 
Physicochemical properties:It isawhite to off-white crystalline powder. 
Solubility   : Tenofovir disoproxil fumarate e has is a solubility of  
                                                 approximately 13.4 mg/mL in distilled water at 25°C. 
pKa    :2.65 
Polar Surface Area  :172.47 ?2 
Flash Point   : 342.5 °C ; 
Enthalpy of Vaporization : 94.85 kJ/mol ; 
Boiling Point   : 642.7 °C at 760 mmHg ; 
Vapour Pressure  : 2.06E-16 mmHg at 25°C 
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The Tenofovir disoproxil fumarate has a brand name VIREAD. It is obtained from a 
fumaric acid salt of bis-isopropoxycarbonyloxymethyl ester derivative of tenofovir. 
Tenofovir disoproxil fumarate is converted to tenofovir, which is an acyclic 
nucleoside phosphonate (nucleotide) analog of adenosine 5'-monophosphate. 
Tenofovir exhibits activity against HIV-1 reverse transcriptase. Tenofovir disoproxil 
fumarate is  taken orally .  
 
INTERACTIONS 
Tenofovir disoproxil fumarate is indicated in combination with other antiretroviral 
agents for the treatment of HIV-1 infection in adults. 
 
DOSAGE AND ADMINISTRATION 
Recommended Dose 
For the treatment of HIV-1 or chronic hepatitis B.The dose of Tenofovir disoproxil 
fumarate is 300 mg once daily taken orally, without regard to food. 
 
SIDE EFFECTS 
The following adverse reactions are discussed in other sections of the labeling: 
 Lactic Acidosis/Severe Hepatomegaly with Steatosis 
 Severe Acute Exacerbation of Hepatitis New Onset or Worsening Renal 
Impairment Decreases in Bone Mineral Density  
 Immune Reconstitution Syndrome  
 
ADVERSE REACTIONS 
Immune System Disorders 
allergic reaction, including angioedema 
 
Metabolism and Nutrition Disorders 
lactic acidosis, hypokalemia, hypophosphatemia 
 
Respiratory, Thoracic, and Mediastinal Disorders  
dyspnea 
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Gastrointestinal Disorders 
pancreatitis, increased amylase, abdominal pain 
 
Hepatobiliary Disorders 
hepaticsteatosis, hepatitis, increased liver enzymes (most commonly AST, ALT 
gamma GT) 
 
Skin and Subcutaneous Tissue Disorders 
rash 
 
Musculoskeletal and Connective Tissue Disorders 
rhabdomyolysis, osteomalacia (manifested as bone pain and which may contribute to 
fractures), muscular weakness, myopathy 
 
Renal and Urinary Disorders  
acute renal failure, renal failure, acute tubular necrosis, Fanconi syndrome, proximal 
renal tubulopathy, interstitial nephritis (including acute cases), nephrogenicdiabetes 
insipidus, renal insufficiency, increased creatinine, proteinuria, polyuria 
The following adverse reactions, listed under the body system headings above, may 
occur as a consequence of proximal renal tubulopathy: rhabdomyolysis, osteomalacia, 
hypokalemia, muscular weakness, myopathy, hypophosphatemia. 
 
DRUG INTERACTIONS 
This section describes clinically relevant drug interactions with VIREAD. Drug 
interactions studies are described elsewhere in the labeling 
 
Didanosine 
Coadministration of Tenofovir disoproxil fumarate and didanosine should be 
undertaken with caution and patients receiving this combination should be monitored 
closely for didanosine-associated adverse reactions. Didanosine should be 
discontinued in patients who develop didanosine-associated adverse reactions 
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Atazanavir 
Atazanavir has been shown to increase tenofovir concentrations The mechanism of 
this interaction is unknown.  
 
Lopinavir/Ritonavir 
Lopinavir/ritonavir has been shown to increase tenofovir concentrations The 
mechanism of this interaction is unknown.  
 
CLINICAL PHARMACOLOGY 
Mechanism of Action 
Tenofovir disoproxil fumarate is an antiviral drug. 
 
Pharmacokinetics 
The pharmacokinetics of tenofovir disoproxil fumarate have been evaluated in healthy 
volunteers and HIV-1 infected individuals. Tenofovir pharmacokinetics are similar 
between these populations. 
 
Absorption 
Tenofovir disoproxil fumarate is a water soluble diesterprodrug of the active 
ingredient tenofovir. The oral bioavailability of tenofovir from Tenofovir disoproxil 
fumarate in fasted subjects is approximately 25%.  
The pharmacokinetics of tenofovir are dose proportional over a Tenofovir disoproxil 
fumarate dose range of 75 to 600 mg and are not affected by repeated dosing. 
 
Distribution 
In vitro binding of tenofovir to human plasma or serum proteins is less than 0.7 and 
7.2%, respectively, over the tenofovir concentration range 0.01 to 25 μg/mL. 
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Metabolism and Elimination 
Tenofovir is eliminated by a combination of glomerular filtration and active tubular 
secretion. There may be competition for elimination with other compounds that are 
also renally eliminated. 
 
MICROBIOLOGY 
Mechanism of Action 
Tenofovir disoproxil fumarate is an acyclic nucleoside phosphonatediesteranalog of 
adenosine monophosphate. Tenofovir disoproxil fumarate requires initial diester 
hydrolysis for conversion to tenofovir and subsequent phosphorylations by cellular 
enzymes to form tenofovirdiphosphate, an obligate chain terminator. Tenofovir 
diphosphate inhibits the activity of HIV-1 reverse transcriptase and HBV polymerase 
by competing with the natural substrate deoxyadenosine 5'-triphosphate and, after 
incorporation into DNA, by DNA chain termination. Tenofovir diphosphate is a weak 
inhibitor of mammalian DNA polymerases α, β, and mitochondrial DNA polymerase 
γ. 
 
Activity against HIV 
Antiviral Activity  
The antiviral activity of tenofovir against laboratory and clinical isolates of HIV-1 
was assessed in lymphoblastoid cell lines, primary monocyte/macrophage cells and 
peripheral blood lymphocytes.  
 
Resistance:HIV-1 isolates with reduced susceptibility to tenofovir have been 
selected in cell culture. These viruses expressed a K65R substitution in reverse 
transcriptase and showed a 2–4 fold reduction in susceptibility to tenofovir. 
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6.EXCIPIENT PROFILE
 
 
6.1 STARCH 1500
(36) 
Nonproprietary Names
 
BP: Pregelatinised Starch PhEur: Starch, Pregelatinised USP-NF: Pregelatinized 
Starch 
 
Synonyms 
Amylumpregelificatum; compressible starch; C*PharmGel; Instastarch; Lycatab C; 
Lycatab PGS; Merigel; National 78-1551; Pharma-Gel; Prejel; Sepistab ST200; 
Spress B820; Starch 1500 G; Tablitz; Unipure LD; Unipure WG220. 
 
Chemical Name and CAS Registry Number 
Pregelatinized starch [9005-25-8] 
 
Empirical Formula and Molecular Weight 
(C6H10O5)n where n = 300–1000. 
Pregelatinized starch is a starch that has been chemically and/or mechanically 
processed to rupture all or part of the starch granules. Both fully and partially 
pregelatinized grades are commercially available. Partial pregelatinization renders the 
starch flowable and directly compressible. Full pregelatinization produces a cold-
water soluble starch that can be used as a wet granulation binder. Typically, 
pregelatinized starch contains 5% of free amylose, 15% of free amylopectin, and 80% 
unmodified starch. The USP32–NF27 does not specify the botanical origin of the 
original starch, but the PhEur 6.3 specifies that pregelatinized starch is obtained from 
maize (corn), potato, or rice starch. See also Starch and Section 13. Normally the fully 
pregelatinized starch contains 20–30% amylose and the rest amylopectin, which is 
about the same ratio (1 : 3) as for the partially pregelatinized form. There are ways to 
increase the amylose portion. 
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Structural Formula 
 
 
Functional Category 
Tablet and capsule diluent; tablet and capsule disintegrant; tabletnbinder. 
 
Applications in Pharmaceutical Formulation or Technology 
Partially pregelatinized starch is a modified starch used in oral capsule and tablet 
formulations as a binder, diluent,anddisintegrant. In comparison to starch, partially 
pregelatinized starch may be produced with enhanced flow and compression 
characteristics such that the pregelatinized material may be used as a tablet binder in 
dry compression or direct compression processe. In such processes, pregelatinized 
starch is self-lubricating.  
 
Stability and Storage Conditions 
Pregelatinized starch is a stable but hygroscopic material, which should be stored in a 
well-closed container in a cool, dry place. 
 
Safety 
Pregelatinized starch and starch are widely used in oral solid-dosage formulations. 
Pregelatinized starch is generally regarded as a nontoxic and nonirritant excipient. 
However, oral consumption of large amounts of pregelatinized starch may be harmful. 
 
 
Handling Precautions 
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Observe normal precautions appropriate to the circumstances and quantity of material 
handled. Eye protection and a dust mask are recommended. Excessive dust generation 
should be avoided to minimize the risks of explosions. 
 
Regulatory Status 
Included in the FDA Inactive Ingredients Database (oral capsules, suspensions, and 
tablets; vaginal preparations). Included in nonparenteral medicines licensed in the 
UK. 
 
Related Substances 
Corn starch and pregelatinized starch; starch; starch, sterilizablemaize. 
 
Applications in Pharmaceutical Formulation or Technology 
Pregelatinized starch is a modified starch used in oral capsule and tablet formulations 
as a binder, diluent,anddisintegrant.In comparison to starch, grades of pregelatinized 
starch may be produced with enhanced flow and compression characteristics such that 
the pregelatinized material may be used as a tablet binder in dry-compression or direct 
compression processes. In such processes, pregelatinized starch is self-lubricating. 
However, when it is used with other excipients it may be necessary to add a lubricant 
to a formulation.  
Although magnesium stearate 0.25 w/w is commonly used for this purpose, 
concentrations greater than this may have adverse effects on tablet strength and 
dissolution.  
 
Table-3 Uses of pregelatinized starch. 
Use Concentration (%) 
Diluent (hard gelatin capsules) 5–75 
Tablet binder (direct compression) 5–20 
Tablet binder (wet granulation) 5–10 
Tablet disintegrant 5–10 
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6.2 HYDROXYPROPYL CELLULOSE, LOW-SUBSTITUTED
(36) 
Nonproprietary Names 
JP: Low Substituted Hydroxypropylcellulose 
USP-NF: Low-Substituted Hydroxypropyl Cellulose 
 
Synonyms 
Cellulose, 2-hydroxypropyl ether; 2-hydroxypropyl ether (lowsubstituted) 
cellulose; hyprolose, low-substituted; L-HPC; oxypropylated cellulose. 
 
Chemical Name and CAS Registry Number 
Cellulose, 2-hydroxypropyl ether (low-substituted) [9004-64-2] 
 
Empirical Formula and Molecular Weight 
C36H70O19  and 576.762 
 
Structural Formula 
 
 
Functional Category 
Tablet and capsule disintegrant; tablet binder. 
 
Applications in Pharmaceutical Formulation or Technology 
Low-substituted hydroxypropyl cellulose is widely used in oral solid-dosage forms. It 
is primarily used as a disintegrant, and as a binder for tablets and granules in wet or 
dry granulation. It has been used in the preparation of rapidly disintegrating tablets 
produced by direct compression methods. In addition, low substitutedhydroxypropyl 
cellulose has been used as a binder/ disintegrant included in the powder layering 
58 
 
process on spherical cores and to prepare pellets by extrusion/spheronization. A low 
particle size and high hydroxypropyl content is recommended to produce round 
spheres and rapid dissolution. 
          The typical content of low-substituted hydroxypropyl cellulose in a formulation 
is approximately 5–50%. 
 
Description 
Low-substituted hydroxypropyl cellulose occurs as a white to yellowish white powder 
or granules. It is odourless or has a slight, characteristic odor, and it is tasteless. 
 
Solubility 
Completely insoluble in water, and alcohol. Dissolves in 10% NaOH solution to give 
a viscous solution.Swells rapidly in water.  
 
Physical Characteristics 
PH (slurry): 5.0 –7.5  
Loss on Drying: £ 5.0% 
Table-4 HPC Characteristics 
Product 
Average Particle 
size (microns) 
Hydroxypropyl 
content 
Bulk Density 
(g/cc) 
LH-11 50 Medium 0.34 
LH-21 40 Medium 0.40 
LH-31 25 Medium 0.30 
LH-22 40 Low 0.37 
LH-32 25 Low 0.21 
LH-20 40 High 0.36 
LH-30 25 High 0.25 
 
Stability and Storage Conditions 
Low-substituted hydroxypropyl cellulose is a stable, though hygroscopic, material. 
The powder should be stored in a well closed container. 
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Incompatibilities 
Alkaline substances may interact. If a tablet formulation contains such a material, the 
disintegration time may be extended after storage. 
 
Method of Manufacture 
Low-substituted hydroxypropyl cellulose is manufactured by reacting alkaline 
cellulose with propylene oxide at elevated temperature. Following the reaction, the 
product is recrystallized by neutralization, washed, and milled. 
 
Safety 
Low-substituted hydroxypropyl cellulose is generally regarded as a nontoxic and non-
irritant material. Animal toxicity studies showed no adverse effects in rats fed orally 6 
g/kg/day over 6 months. No teratogenicity effects were noted in rabbits and rats fed 5 
g/kg/day.(8–11) LD50 (rat, oral): >15 g/kg(8) 
 
Handling Precautions 
Observe normal precautions appropriate to the circumstances and quantity of material 
handled. Excessive dust generation should be avoided to minimize the risk of 
explosions. 
 
Regulatory Status 
Included in the FDA Inactive Ingredients Database (oral capsules, tablets, pellets). 
Approved for use in pharmaceuticals in Europe,Japan, USA, and other countries. 
Included in the Canadian List of Acceptable Non-medicinal Ingredients. 
 
Related Substances 
Hydroxyethylmethyl cellulose; hydroxypropyl cellulose; methylcellulose. 
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Applications 
 
Table-5 HPCLH-11 Applications 
Disintegrant Wet granulated and directly compressed tablets.   
Types with a larger average particle size  and higher 
hydroxypropyl content show higher degree of swelling. 
Binder Direct compression.   
LH-22 provides greater binding while retaining disintegration 
properties. Binder levels are in the 25% range.   
 LH-11 is useful to prevent capping.  
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6.3LYCATABC ( pregelatinized starch )
(36) 
Nonproprietary Names 
BP: Maize starch Potato starch Rice Starch Tapioca Starch Wheat Starch 
JP: Corn Starch Potato Starch Rice Starch Wheat Starch 
PhEur: Maize Starch Pea Starch Potato Starch Rice Starch Wheat Starch 
USP-NF: Corn Starch Potato Starch Tapioca Starch Wheat Starch 
 
Empirical Formula and Molecular Weight 
(C6H10O5)n where n = 300–1000. 
 
Particle size 
Mean particle size: 100 µm, Low dust content 
 
Properties 
 Free flowing powder  
 High Density  
 Dispersible and partially soluble in cold water 
 High powder cohesion  
 Compatible with gelatin 
 
 Applications  
 Filler disintegrant for hard gelatin capsules 
 Binder disintegrant for direct compression  
 Flow aid in powder blends 
 
Functional Category 
Tablet and capsule diluent; tablet and capsule disintegrant; tablet binder; thickening 
agent. 
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Description 
Starch occurs as an odorless and tasteless, fine, white to off-white powder. It consists 
of very small spherical or ovoid granules or grains whose size and shape are 
characteristic for each botanical variety. 
 
Stability and Storage Conditions 
Dry starch is stable if protected from high humidity. Starch is considered to be 
chemically and microbiologically inert under normal storage conditions. Starch 
solutions or pastes are physically 
unstable and are readily metabolized by microorganisms; they should therefore be 
freshly prepared when used for wet granulation. Starch should be stored in an airtight 
container in a cool, dry place. 
 
Incompatibilities 
Starch is incompatible with strongly oxidizing substances. Colored inclusion 
compounds are formed with iodine. 
 
Method of Manufacture 
Starch is extracted from plant sources with specific processes according to the 
botanical origin. Typical production steps are steeping (corn), wet milling (corn, 
potato), dry milling (wheat), or sieving and physical separation with hydro cyclones. 
The last production step is usually a centrifugal separation from the starch slurry 
followed by drying with hot air. The starch separation process may use sulfur dioxide 
or peroxides as a processing aid, improving the separation process and the microbial 
quality of the final product. 
 
Safety 
Starch is an edible food substance, considered a food ingredient and not a food 
additive. It is regarded as an essentially nontoxic andnonirritant material. Starch is 
therefore widely used as anexcipient in pharmaceutical formulations. 
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6.4.SodiumStearyl Fumarate
(36) 
Nonproprietary Names 
BP: Sodium Stearyl Fumarate 
PhEur: Sodium Stearyl Fumarate 
USP-NF: Sodium Stearyl Fumarate 
 
Synonyms  
Fumaric acid, octadecyl ester, sodium salt; natriistearylisfumaras; 
Pruv; sodium monostearyl fumarate. 
 
Chemical Name and CAS Registry Number 
2-Butenedioic acimd,onooctadecyl ester, sodium salt [4070-80-8]  
 
Empirical Formula and Molecular Weight 
C22H39NaO4  and 390.5 
 
Structural Formula 
 
 
 
Functional Category 
Tablet and capsule lubricant. 
 
Applications in Pharmaceutical Formulation or Technology 
Sodium stearyl fumarate is used as a lubricant in capsule and tablet 
formulations at 0.5–2.0% w/w concentration.(1–9) It is also used in 
certain food applications; 
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Description 
Sodium stearyl fumarate is a fine, white powder with agglomerates 
of flat, circular-shaped particles. 
 
Typical Properties 
Acidity/alkalinity pH = 8.3 for a 5% w/v aqueous solution at908C. 
Density 1.107 g/cm3 
Density (bulk) 0.2–0.35 g/cm3 
Density (tapped) 0.3–0.5 g/cm3 
Specific surface area 1.2–2.0m2/g 
 
Stability and Storage Conditions 
At ambient temperature, sodium stearyl fumarate is stable for up to3 years when 
stored in amber glass bottles with polyethylene screw caps. 
                 The bulk material should be stored in a well-closed container in a 
cool, dry place. 
 
Incompatibilities 
Sodium stearyl fumarate is reported to be incompatible with chlorhexidine acetate. 
 
Method of Manufacture 
Stearyl alcohol is reacted with maleic anhydride. The product of this reaction then 
undergoes an isomerization step followed by salt formation to produce sodium stearyl 
fumarate. 
 
Safety 
Sodium stearyl fumarate is used in oral pharmaceutical formulations and is generally 
regarded as a nontoxic and non-irritant material. Metabolic studies of sodium stearyl 
fumarate in the rat and dog indicated that approximately 80% was absorbed and 35% 
wasrapidly metabolized. The fraction absorbed was hydrolyzed to stearyl alcohol and 
fumaric acid, with the stearyl alcohol further oxidized to stearic acid. In the dog, 
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sodium stearyl fumarate that was not absorbed was excreted unchanged in the feces 
within 24hours. 
Stearyl alcohol and stearic acid are naturally occurring constituents in various 
food products, while fumaric acid is a normal constituent of body tissue. Stearates and 
stearyl citrate have been reviewed by the WHO and an acceptable daily intake for 
stearyl citrate has been set at up to 50 mg/kg body-weight. The establishment of an 
acceptable daily intake for stearates and fumaric acid was thought unnecessary. 
Disodium fumarate has been reported to have a toxicity not greatly exceeding that of 
sodium chlorid 
 
Handling Precautions 
Observe normal precautions appropriate to the circumstances and quantity of material 
handled. Sodium stearyl fumarate should be handled in a well-ventilated environment; 
eye protection is recommended. 
 
Regulatory Status 
GRAS listed. Permitted by the FDA for direct addition to food for human 
consumption as a conditioning or stabilizing agent in various bakery products, flour-
thickened foods, dehydrated potatoes, and processed cereals up to 0.2–1.0% by 
weight of the food. Included in nonparenteral medicines licensed in the UK.Included 
in the FDA Inactive Ingredients Database (oral capsules and tablets).Included in the 
Canadian List of Acceptable Non-medicinal Ingredients. 
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7.INNOVATOR PRODUCT CHARACTERIZATION 
 
Generic name        : Emtricitabine and Tenofovir disoproxil fumarate tablets 
 
Brand name             :TRUVADA 
  
Manufactured By :Gilead Sciences Limited 
 
Storage condition :Store at 15–30 °C (59–86 °F). 
 
Dosage Form  : Tablet 
 
Strength  : 200/300mg 
 
Description  :TRUVADA tablets are blue, capsule-shaped, film-coated,  
                                      debossed with "GILEAD" on one side and with "701" on the     
                                      other side 
 
Pack details  :TRUVADA tablets are packed in HDPE bottle containing    
                                      silica gel desiccant with a child resistant cap containing an  
                                      aluminium foil inner seal. 
 
Tablet weight   : Avg.Weight:1030mg 
 
Uncoated/coated  : Coated (Film coating)  
 
Thickness (mm)  : 6.48-6.86 
 
Hardness (k/cm
2
)  : 26.5-27.5 
 
Disintegration time  : 11 min 30 sec 
 
 
67 
 
Figure-4 Innovator Product 
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8.  MATERIALS AND METHODS 
 
Table-6  List of materials 
  
 
 
Name of Drug/Excipients 
Brand Name / 
Grade 
Source 
Emtricitabine USP Arch Pharmalabs Ltd. 
Tenofovir disoproxil fumarate USP Arch Pharmalabs Ltd. 
Microcrystalline Cellulose pH  
102 
USP Vijilakpharma 
Di Calcium Phosphate USP Vijilakpharma 
Pregelatinized  starch Lycotab-c 
Signet Chemical Corporation 
Pvt Ltd. 
Hydroxy Propyl Cellulose LH-
II 
USP Colorcon Asia Pvt Ltd 
Sodium Steryl Fumarate USP Amisti Drugs Ltd 
Glycerol Bentoate USP 
Signet Chemical Corporation 
Pvt Ltd. 
Starch 1500 USP Amisti Drugs Ltd 
Opadry II Blue (Y-30-1070) - Colorcon Asia Pvt Ltd. 
69 
 
Table-7  List of equipments 
NAME OF INSTRUMENT MODEL  AND MANUFACTURER 
Digital Balance Mettler Toledo PR203 
Rapid Mix Granulator RMG5 Anchor Mark Pvt Ltd 
Fluid bed dryer UmangPharmatech Pvt Ltd,Mumbai 
Moisture Analyzer Advance Research Instruments 
Tap Density Tester USP Electrolab,Mumbai 
Tabletting Machine-27Stn Rimek,Ahmedabad 
Vernier Calliper Mitutoyo,China 
Hardness Tester SQC & Inspection instruments,Mumbai 
Disintegration Test Apparatus USP Tab machines 
Friabilator USP Veegoinstruments,Mumbai 
Mechanical Stirrer Neomachine,Mumbai 
Auto coater Neocota,Mumbai 
Dissolution Apparatus USP XXII ElectroLab,Ahmedabad 
HPLC with Autosampler Waters ,USA 
pH meter Metro HM ,Switzerland 
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Table-8 APICharacterization -Emtricitabine 
S.No. Test Specification 
01 Description White to off white  powder 
02 Solubility 
Freely Soluble in dimethyl formamide  
and soluble in methanol. 
 
03 Water content(%w/w) Should be not more than  1.0 %w/w 
04 Melting range( 
o
 c) 114 to 118 
05 Residue on ignition(%w/w) Should be not more than  0.2 %w/w 
06 Heavy metals(ppm) Should be not more than  20%w/w 
07 
Fumaric acid content by 
potentiometry (%w/w) (on 
anhydrous basis) 
 
17.5 – 19 
08 
S-Isomer content by chiral HPLC 
(%area) 
Should be not more than  1 %w/w 
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Table-9 Related compounds of Emtricitabine BY HPLC 
 
 
 
 
01 
Related compounds by HPLC 
A) 
 
Method -1(%w/w) 
 
 
a) Sulfoxide-I impurity 
Should be not more than 0.2% 
 
b) Sulfoxide-II impurity 
Should be not more than 0.2% 
 
c) 5 Flourocystine  impurity 
Should be not more than 0.2% 
 
d) Mono ester  impurity 
Should be not more than 0.3% 
 
e) Adenine impurity 
Should be not more than 0.2% 
 
f) Other  impurities 
Should be not more than 1.0% 
 
h) Total impurities 
Should be not more than  2.5% 
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Table-10 API Characterization - Tenofovir disoproxil fumarate 
 
 
 
 
 
 
S.No. Test Specification 
01 Description White to off white  powder 
02 Solubility 
 
Freely Soluble in dimethyl formamide  
and soluble in methanol. 
 
03 Water content(%w/w) Should be not more than  1.0 %w/w 
04 Melting range( 
o
 c) 114 to 118 
05 Residue on ignition(%w/w) Should be not more than  0.2 %w/w 
06 Heavy metals(ppm) Should be not more than  20%w/w 
07 
Fumaric acid content by 
potentiometry (%w/w) (on 
anhydrous basis) 
 
 
17.5 – 19 
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Table-11 Related compounds of Tenofovir Disoproxil Fumarate BY HPLC 
 
 
 
 
 
 
01 
Related compounds by HPLC 
 
A) 
Method -1(%w/w) 
 
 
a) Sulfoxide-I impurity 
Should be not more than 0.2% 
b)Sulfoxide-II impurity 
Should be not more than 0.2% 
c) 5 Flourocystine  impurity 
Should be not more than 0.2% 
d) Mono ester  impurity 
Should be not more than 1% 
e) Adenine impurity 
Should be not more than 0.2% 
f) Other  impurities 
Should be not more than 1.0% 
h) Total impurities 
Should be not more than  2.5% 
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8.1 PREFORMULATION STUDIES 
8.1.1 Compatibility Studies
(37,38) 
A Compatibility study focuses on a binary mixture of drug substance and 
some selected excipients in a fixed ratio with or without added moisture.The mixture 
is stored at  elevated temperatures of 40
o
c 75%RH and 55
O
C 60%RH in capped vials. 
The  interaction between the active drug and excipients is determined by HPLC. The 
results were given in table 23,24,25,26. 
Procedure 
1. Drug and Excipients mixture shall be prepared based on the information from 
Physician Desk Reference (PDR). 
2. The Drugs and Excipients individually and in combination shall be subjected 
for accelerated study conditions along with control samples and study at fixed 
intervals 
3. The recommended drug- excipients ratios for solid dosage forms are tabulated 
below 
Table-12 Drug excipient ratios for solid dosage forms 
Name of 
Excipient 
Quantity of Drug in mg 
< 5 
mg 
5  
10mg 
10  
50mg 
50  
200mg 
200  
500mg 
500 
mg 
Fillers & 
Diluents 
1:40 1:20 1:10 1:5 1:2 1:1 
Disintegrants 
/ Polymers 
1:10 1:5 1:1 1:1 1:0.5 1:0.25 
Binders 1:10 1:5 1:1 1:0.5 1:0.25 1:0.1 
Lubricants 1:0.5 1:0.5 1:0.25 1:0.1 1:0.05 1:0.05 
Coating 
agents 
1:5 1:5 1:1 1:0.5 1:0.25 1:0.1 
Colours / 
Sweetners 
1:0.05 1:0.05 1:0.05 1:0.05 1:0.05 1:0.05 
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Table-13Study conditions and parameters to be analysed 
Name of the drug/excipients Ratio 
Test Parameters 
Initial 
Period-14 & 28 Days 
55°C/60%RH 40°C/75%RH 
Emtricitabine   (200mg) - RS&A RS & A RS & A 
Tenofovir disoproxil 
fumarate(300mg) 
- RS&A RS & A RS & A 
Emtricitabine+ Tenofovir 
disoproxil 
fumarate+microcrystalline 
cellulose PH 102 
1:2 RS&A RS & A RS & A 
Emtricitabine+ Tenofovir 
disoproxil fumarate+ Di Calcium 
Phosphate 
1:2 RS&A RS & A RS & A 
Emtricitabine+ Tenofovir 
disoproxil fumarate+ Starch1500 
1:1 RS&A RS & A RS & A 
Emtricitabine+ Tenofovir 
disoproxil fumarate+ Lycatab-c 
1:1 RS&A RS & A RS & A 
Emtricitabine+ Tenofovir 
disoproxil fumarate+ Hydroxy 
Propyl Cellulose LH-11 
1:1 RS&A RS & A RS & A 
Emtricitabine+ Tenofovir 
disoproxil fumarate+ Sodium 
Steryl Fumarate 
1: 0.1 RS&A RS & A RS & A 
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Emtricitabine+ Tenofovir 
disoproxil fumarate+ Glycerol 
Bentoate 
1:0.1 RS&A RS & A RS & A 
Emtricitabine+ Tenofovir 
disoproxil fumarate+coating 
agent(OpadryBlue-II) 
1:0.1 RS&A RS& A RS & A 
Placebo+Emtricitabine 1:1 RS&A RS & A RS & A 
Placebo+tenofovir disoproxil 
fumarate 
1:1 RS&A RS & A RS & A 
Placebo+emtricitabine+tenofovir 
disoproxil fumarate 
1:1 RS&A RS & A RS & A 
 
Where, API = Active Pharmaceutical Ingredient (Clopidogrel Bisulphate),RS = 
Related substances, A = Appearance. 
 
8.1.2 Angle of repose
(39,40,41)
 
 Angle of Repose is defined as the maximum angle possible between the 
surface of a pile of the powder and the horizontal plane.The angle of repose is 
determined by funnel method.The funnel is fixed at a particular height (2.5 cm)on a 
burette stand.The powder sample was passed through the funnel allowing it to form a 
pile.No more granules are added as the pile touches the tip of the funnel.This region is 
encircled to measure radius.The same procedure is done for triplicate,the average 
value is taken.The values are given in table28The angle of repose is calculated by 
using equation. 
 
 
 
 
Angle of Repose (θ) =Tan -1 (h/r) 
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Where, h = height of pile 
      r = radius of the base of the pile 
      θ = angle of repose 
 
                  Table-14 Angle of repose and corresponding flow properties 
Angle of Repose Flow property 
<25 
25-30 
30-40 
>40 
Excellent 
Good 
Passable 
Very Poor 
 
8.1.3 Bulk density determination
(39,40,41)
 
 Weighed quantity of the powder (W) is taken in a graduated measuring cylinder 
and volume (V0) is measured  the reading were shown in table 28. Bulk density is 
calculated using the formula.  
 
Bulk density (BD) = Weight of the powder/ Volume of powder 
 
8.1.4 Tapped density determination
(39,40,41)
  
Weighed quantity of powder(W) is taken in a graduated cylinder and the volume is 
measured. The graduated cylinder was fixed in the „Tapped Densitometer‟ and tapped 
for 500, 750 and 1250 times until the difference in the volume after consecutive 
tappings was less than 2%.  The final reading was denoted by (Vf). The volume of 
blend was used to calculate the tapped density, Hausner‟s ratio and Carr‟s Index.The 
reading were shown in table 28. 
 
Tapped density (TD)  = W/Vf g/ml 
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8.1.5 Carr’s index(39,40,41) 
Carr‟s index is also known as compressibility. It is indirectly related to the relative 
flow rate, cohesiveness and particle size. It is simple, fast and popular method of 
predicting powder flow characteristics. 
 
Table-15  Carr’s index and corresponding flow properties 
 
 
 
Carr‟s index was calculated by using the formula: 
    Carr’s Index   =  (Tapped Density –Bulk Density) x   100                                                 
                                                   Tapped Density 
  
8.1.6 Hausnerratio
(39,40,41)
 
Hausner ratio indicates the flow properties of the powder and measured by the ratio of 
tapped density to bulk density.  The relationship between Hauser‟s ratio and flow 
property 
                  Table-16Hausner ratio and corresponding flow properties 
Hausner Ratio Property 
0-1.2 Free flowing 
1.2-1.6 Cohesive Powder 
 
Hausner ratio was calculated by using the formula. 
Hausner Ratio   =   Tapped density / Bulk density 
Hausner Ratio    =    V0 
Vf 
Carr’s Index (%) Flow 
5-15 
16-18 
18-21 
23-35 
33-38 
>40 
Excellent 
Good 
Fair to passable 
Poor 
Very poor 
Very very poor 
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 Where,   V0= Initial volume  
               Vf = Final volume 
 
8.2 SELECTION OF EXCIPIENTS 
The following are the excipients selected from the compatibility studies. 
 Emtricitabine  
 Tenofovir disoproxil fumarate 
 DiCalcium Phosphate 
 Starch 1500 
 Pregelatinized Starch(lycotab-c) 
 Hydro Propoxy Cellulose(HPC) LH-11 
 Sodium Steryl Fumarate 
 Opadry Blue  II 
 
8.3PREPARATION OF STANDARD GRAPH OF 
TENOFOVIR AND EMTRICITABINE 
Standard Stock Solution 
Tenofovir and Emtricitabine were weighed separately (100 mg) and dissolved 
in buffer and made up to 100ml in volumetric flasks to get a concentration of 
1000μg/ml. 
 
Calibration Graph 
The standard stock solution of TDF was diluted to get a concentration ranging 
5-30 μg/ml. The absorbance of the resulting solutions were measured at 257 nm. 
Similar procedure was followed for EMB and absorbance measured at 280 nm by 
using high pressure liquid chromatography(HPLC). It was found that the TDF and 
EMB showed good linearity at concentrations ranging 5-30 μg/ml. the readings were 
showed in table 27 and the fig 6 & 7. 
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8.4 working formulae                                       Table 17: Working Formulae 
S.No. Ingredients Rationale 
                               Quantity for Single  Tablet 
F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 
1. Emtricitabine API 
200 200 200 
200 200 200 200 200 200 200 
2. 
Tenofovir disoproxil 
fumarate 
API 
300 300 300  
300 
 
300 
 
300 
 
300 
 
300 
 
300 
 
300 
3. DiCalcium Phosphate Diluent 
390 390 390 
390 390 390 340 340 410 370 
4. Starch 1500 Disintegrant 
60 60 60  
60 
 
80 
 
---- 
 
---- 
 
---- 
 
--- 
 
--- 
5. 
Lycatab c 
(pregalatinized starch) 
Disintegrant 
---- ---- ---- 
---- --- 60 80 ---- ---- ---- 
6. 
Hydroxy Propyl  
Cellulose(HPC)LH-11 
 
Disintegrant 
---- ---- ----  
---- 
 
---- 
 
--- 
 
---- 
 
60 
 
50 
 
80 
7. Water Vehicle 
---- ---- Q.s 
---- ---- ---- ---- ---- ---- ---- 
8. 
Iso Propyl Alcohol+ 
Water(80:20) 
Vehicle 
---- ---- ----  
Q.s 
 
Q.s 
 
Q.s 
 
Q.s 
 
Q.s 
 
Q.s 
 
Q.s 
9. Starch 1500 Disintegrant 
40 40 40  
40 
 
40 
 
---- 
 
---- 
 
---- 
 
--- 
 
--- 
10. Lycatab c Disintegrant 
---- ---- ---- 
---- --- 40 40 ---- ---- ---- 
11. 
Hydroxy Propyl  
Cellulose(HPC)LH-11 
Disintegrant 
---- ---- ---- 
---- ---- --- ---- 40 30 40 
12. Sodium Steryl Fumarate Lubricant 
10 10 10  
10 
 
10 
 
10 
 
10 
 
10 
 
10 
 
10 
13. Opadry Blue II Film former 
30 30 30 
30 30 30 30 30 30 30 
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8.5 METHOD OF PREPARATIONS 
Process Validation 
DIRECT COMPREESION(F1) 
Objective 
 FormualtionFI (table17) of Emtricitabine and Tenofovir disoproxil fumarate tablets 
by Prepared Direct compression method. 
 
Procedure:(Direct Compression) 
 
Dispensing of API + Excipients 
↓ 
D.C.P + Starch1500 Shifted through 40# 
↓ 
Emtricitabine + Tenofovir Shifted through 24# 
         ↓Lubricated  
Sodium steryl fumarate + Starch1500 
↓ 
Direct Compression 
( 19×8.5 Punch Capsule shape) 
↓ 
Coating 
                                             (Opadry solution (15%)) 
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DRY GRANULATION(F2) 
Objective 
To take a trial batch of Emtricitabine and Tenofovir disoproxil fumarate tablets by 
Dry Granulation Method.                                                                                                                                                                                                                                                                      
Procedure 
Step I 
Dispensing 
 The dispensing of active pharmaceutical ingredient and Excipients was carried out 
in dispensing booth as per manufacturing formula.  
 
Step II 
Emtricitabine and Tenofovir disoproxil fumarate DiCalcium Phosphate and 
Starch1500 were mixed sifted through #30 meshes. 
 
Step II 
Slugs were Prepared by punching of the above mixture 
 
Step IV 
Theprepared  Slugs were crushed by using Rollercompression and the granules 
were pass through  18# mesh. 
 
Step V 
The dry granules were lubricated with Sodium Steryl Fumarate and starch1500 
which were previously passed through 30#mesh.  
 
Step VI 
The lubricated powder was compressed into tablets by using 19*8.5 punch (capsule 
shape)  
 
Step VII 
The prepared tablets were coated by using opadry blue solution.  
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WET GRANULATION (F3) (Only with Water) 
Objective 
The formulation F3 of Emtricitabine and Tenofovir disoproxil fumarate  tablets were 
prepared  by  wet- granulation method by using  water as vehicle. 
 
Procedure 
Step I 
Dispensing 
The dispensing of  active pharmaceutical ingredient and excipients was carried out 
in dispensing booth as per manufacturing formula.  
 
Step II 
Emtricitabine and Tenofovir disoproxil fumarate, DiCalcium Phosphate and 
Starch1500 were mixed sifted through #30 mesh and the granules were prepared 
with the vehicle and pass through 12# mesh. 
 
Step III 
The granules were dried in tray dryer at 55
0
C. the dry granules were pass through 
18# mesh and lubricated with sodium sterylrumarate and starch1500 
 
Step IV 
The lubricated powder was compressed into tablets by using 19*8.5 punch (capsule 
shape)  
 
StepV 
Then finally  tablets were coated by using the Opadry blue solution. 
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WET GRANULATION (F4)  Procedure-II 
Due to presence of impurities found in the wet granulation prepared with water as 
vehicle. The vehicle was changed to mixture of IPA and Water (80:20). The 
remaining procedure was same as above.   F5- F10 the same procedure of F4 was 
followed by changing the disintegrants by changing the concentration(Starch1500, 
Lycatab C and HPCLH-11) 
 
Figure-5  Prepared Emtricitabine and Tenofovir disoproxil 
fumarate immediate release tablets. 
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8.6EVALUATION OF TABLETS 
Evaluation of tablets 
Determination of physicochemical parameters of final tablets 
1. Drug content uniformity 
2. Weight variation 
3. Thickness 
4. Hardness 
5. Friability 
6. Disintegration Test 
7. Dissolution studies 
8. chromatographic method (HPLC) 
9. Stability studies 
 
8.6.1 Drugcontentuniformity
(42) 
Although the specifications for assay results differ from product to product, 
generally the expected range for individual active ingredient is to be within 90%–
110% of the labeled amount.  
 
Instrument 
HPLC equipped with UV detector and data handling system. 
 
Apparatus 
Analytical balance,Volumetric flasks,Pipettes,0.45µ membrane filters. 
 
Chemicals and reagents 
Potassium dihydrogen phosphate -GR grade 
Ortho-phosphoric acid  -HPLC grade 
Purified water-Milli   -Q grade 
Acetonitrile    -HPLC grade 
Emtricitabine working standard 
Tenofovir disoproxil fumarate working standard 
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Chromatographic conditions 
Column:Purosphere star –RP18 , 150 * 4.6 mm,5µm 
Flowrate  :1.0 ml/min 
Wavelength  :UV-254 nm 
Column temperature :30
o
c 
Injection volume :20µl 
Run time  :12 min. 
 
Preparations 
Buffer preparation 
Accurately weigh and transfer about 4.4 gm of Potassium dihydrogen phosphate into 
1000 ml of purified water.Adjust the p
H
 of solution to 3.0 with dilute Ortho-
phosphoric acid. 
 
Mobile phase –A preparation 
 Prepare a filtered and degassed mixture of buffer and Acetonitrile in ratio of 970 
:30 v/v respectively. 
 
Mobile phase –B preparation 
Prepare a filtered and degassed Acetonitrile –HPLC grade ..4. Diluent preparation: 
Mix buffer and Acetonitrile in ratio of 60:40 v/v respectively. 
 
Emtricitabine  and Tenofovir disoproxil fumarate standard 
preparation 
Accurately weigh  and  transfer about 20mg of Emtricitabine working standard and 
30mg of Tenofovir working standard into a 250 ml volumetric flask.  
Add about 180ml of diluents and sonicate  to dissolve.Cool the solution to room 
temperature and dilute to volume with diluents(0.08 mg/ml of Emtricitabine and 
0.12 mg/ml of Tenofovir).Trensfer 2ml of above solution  into a 200ml volumetric 
flask ,mix well and dilute to volume with  Mobile phase –A and mix. 
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Sample preparation 
Weigh and finely powder not fewer than 20 tablets..Transfer  an accurately weighed 
portion of the powder equivalent to 200 mg of emtricitabine into 250ml volumetric 
flask.Add 180ml of diluents.Shake for 10min with rotating shaker and sonicate for 
30min with occasional shakings.Cool the solution to room temperature and dilute to 
volume with diluents and mix.Centrifuge the solution to 3000 rpm for 10 
min.Transfer 1ml of above centrifuged solution into 100ml volumetric flask and 
dilute with Mobile phase –A. 
 
System suitability 
Chromatograph the standard preparation (six replicate injections),measure the peak 
area response for the analyte peak and evaluate the system suitability parameters as 
directed. 
 
Acceptance criteria 
1.%RSD for replication of peak area response due to emtricitabine and tenofovir 
peak from the standard preparation should be not more than 2.0 
2.The tailing factor for emtricitabine and tenofovir peak should be not more than 2.0 
3.The number of theoretical plates for emtricitabine and tenofovir peak should be 
not less than 2000. 
 
Procedure 
Seperately inject equal volumes(about 20µl)of the water as blank,standard 
preparation and sample preparation into chromatograph and record the 
chromatograms and measure the peak area response for analytepeak.Calculate the 
percentage content of  Emtricitabine  and Tenofovir disoproxil fumarate tablets 
taken by formula. The chromatograms were shown in fig 8,9,10,11&12. 
 
Percentage content of Emtricitabine  / Tenofovir disoproxil 
fumarate 
= TA / SA  *  SW / 250  *   2/20   *   250/TW   *  100/1  *  P/100  * AVG WT/ LA  
*  100 
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Where, 
TA  = Peak area response due to Emtricitabine  / Tenofovir disoproxil fumarate 
fromsamplepreparation 
SA= Peak area response due to Emtricitabine  / Tenofovir disoproxil fumarate from    
standard preparation 
SW=Weight of Emtricitabine  / Tenofovir disoproxil fumarate  working standard 
taken in mg. 
TW=Weight of sample taken in mg. 
P=Purity of Emtricitabine  / Tenofovir disoproxil fumarate  working standard taken 
on ,as is basis. 
AVG WT=Average weight of tablets. 
LA=Labelled amount of Emtricitabine  / Tenofovir disoproxil fumarate. 
 
8.6.2WEIGHT VARIATION TEST
(39,43) 
Twenty (20) tablets from each batch were individually weighed. The average weight 
and standard deviation were calculated, individual weight of each tablet was also 
calculated using the same and compared with average weight 
Weight Variation limits as per USP and the values were showed in the table-30. 
 
Table -18 :Weight Variation that has be presented  
solid dosage form 
Average weight in mg % ± deviation allowed 
130 or less 10 
130-324                         7.5 
More than 324 5 
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8.6.3THICKNESS TEST
(39,43)
 
The thickness in millimeters (mm) was measured individually for 10 pre weighed 
tablets by using a Vernier Caliper‟s. The average thickness and standard deviation 
were reported in table-30 and fig 13. 
 
8.6.4HARDNESS TEST
(39,43) 
Tablet hardness was measured using a Monsanto hardness tester. The crushing 
strength of the 10 tablets with known weight and thickness of each was recorded in 
kg/cm
2
 and the average hardness, and the standard deviation was reported and the 
values were shown in the table-30 and fig -14. 
 
8.6.5FRIABILITY TEST
(39,43) 
Twenty (20) tablets were selected from each batch and weighed. Each group of 
tablets was rotated at 25 rpm for 4 minutes (100 rotations) in the Roche friablator. 
The tablets were then dusted and re-weighed to determine the loss in weight. 
Friability was then calculated as per weight loss from the original tablets. The values 
were shown in the table-30. 
 
%Friability= Initial wt- Final wt / Initial wt x100 
 
8.6.6DISINTEGRATION TEST
(44,45) 
The test was carried out on 6 tablets using Tablet disintegration tester.  
Distilled water at 37ºC ± 2ºC was used as a disintegration media and the time 
in seconds taken for complete disintegration of the tablet with no palable mass 
remaining in the apparatus was measured and values shown in the table-30 
and fig -15. 
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 Table-19ThePharmacopoeial specifications for 
                disintegration testing.
 
           Tablet Type                              Time limit and Specifications 
BP 
 Uncoated   <15min 
 Coated 
  Film   <30min 
  Sugar   <60min, repeat in 0.1MHCl 
 Gastro resistant, enteric >120min in 0.1MHCl 
     <60min in pH 6.8(Phosphate) 
 Effervescent   <5min in 200mL, water, 20°C 
 Soluble   <3min 
Dispersible <3min, 2 tablets in 100mL water dispersed, 
passed 7150 um 
 
 
USP 
 Uncoated   <15min  
 Plain coated   <30 min  
            Enteric coated Intact for 60min in simulated gastric fluid, 
disintegrated in simulated intestinal 
fluid<monograph time 
 Buccal    <4hours 
  
 
8.6.7DISSOLUTION TEST 
(37,46)  
Dissolution conditions 
Dissolution studies were performed in a calibrated 8 station dissolution test 
apparatus equipped with paddles (USP apparatus II method) employing 900 ml of 
0.01 N HCL as a medium. The paddles were operated at 50 rpm and temperature 
was maintained at 37 ± 0.5 ºC throughout the experiment. 5 ml samples were 
withdrawn at  5,10, 15, 30 & 45 min of time periods as given by FDA dissolution 
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data base. Equal volume of dissolution medium was replaced to maintain the 
constant volume throughout the experiment. Samples withdrawn and diluted with 
same medium and the amount of the drug dissolved was estimated UV 
spectrophotometer at 254 nm. Dissolution profiles are shown in table 33,34 and fig 
18 &19. 
 
HPLC method 
Instrument 
HPLC equipped with UV detector and data handling system. 
 
Apparatus 
Analytical balance,Volumetric flasks , Pipettes ,0.45µ membrane filters , syringes  
,dissolution apparatus . 
 
Chromatographic conditions 
Column:Purosphere star –RP18 , 150 * 4.6 mm,5µm 
Flowrate  :1.0 ml/min 
Wavelength  :UV-254 nm 
Column temperature :30
o
c 
Injection volume :10µl 
Run time  :12 min. 
 
Preparations 
Mobile phase –A preparation 
 Prepare a filtered and degassed mixture of phosphate buffer pH 3.0 and Acetonitrile 
in ratio of 970 :30 v/v respectively. 
 
Mobile phase –B preparation 
Prepare a filtered and degassed Acetonitrile –HPLC grade. 
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Dissolution test 
Emtricitabine and Tenofovir disoproxil fumarate standard 
preparation 
 Accurately weigh  and  transfer about 22.2mg of Emtricitabine working standard 
and 33.3mg of Tenofovir working standard into a 100 ml volumetric flask. Add 
about 60ml of diluents and sonicate  todissolve.Cool the solution to room 
temperature and dilute to volume with dissolution medium . 
 
Sample preparation 
The dissolution of the tablets was performed by USP typeII paddle apparatus. 
Place one tablet in each of six dissolution flask containing 900ml of dissolution 
medium -(0.01 N HCL) previously maintained at 37
o
c ± 0.5
o
c,taking care to exclude 
air bubbles from the surface of each dosage unit and immediately operate the 
apparatus for 45min.     
5ml were withdraw at specified time interval(5,10,15,30,45) from zone midway 
between the surface of dissolution medium and top of rotating blade,not less than 1 
cm from vessel wall and filter through 0.45 µ membrane filter and analyzed using 
HPLC at 254nm. The same amount of fresh buffer was replaced. The cumulative % 
drug release was plots against time for different formulations.     
 
Percentage content of Emtricitabine  / Tenofovir disoproxil 
fumarate 
 = TA / SA  *   SW / 100  *     900/1  *  P/100  * 100/ LA                                 
 TA  = Peak area response due to Emtricitabine  / Tenofovir disoproxil fumarate 
fromsamplepreparation 
  SA= Peak area response due to Emtricitabine  / Tenofovir disoproxil fumarate from 
standard  preparation 
SW=Weight of Emtricitabine  / Tenofovir disoproxil fumarate  working standard 
taken in mg. 
P=Purity of Emtricitabine  / Tenofovir disoproxil fumarate  working standard taken 
on ,as is basis.  
LA=Labelled amount of Emtricitabine  / Tenofovir disoproxil fumarate. 
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8.6.8 DISSOLUTION PROFILE MODELING 
Over recent year, the In vitro dissolution has been recognized as an important tool in 
drug development. In vitro dissolution has been recognized as an important 
parameter in quality control and under certain conditions, it can be used as a 
surrogate for the assessment of bio-equivalence or prediction of  bioequivalence. 
Guidance recommends USP dissolution apparatus 1, 2, 3 or 4 for modified release 
dosage forms and generally this equipment is satisfactory. However, modifications 
of current dissolution equipment or completely new agitation, changing the media, 
and holding the dosage form in the media without interfering with the release 
mechanism require careful planning.  
              An appropriate drug release test is required to characterize the drug product 
and ensure batch to batch reproducibility and consistent pharmacological/biological 
activity and to evaluate scale up and post approval changes such as manufacturing 
site changes, component and composition changes. The release of drug from a 
sustained release formulation is controlled by various factors through different 
mechanism such as diffusion, erosion or osmosis. Several mathematical models are 
proposed by many researchers to describe the drug release profiles from various 
systems. In order to characterize the kinetics of drug release from dosage forms 
several model dependent methods are reported by various researchers. 
 The model dependent methods all rely upon a curve fitting procedure. Different 
mathematical functions have been used to model the observed data. Both the linear 
and non-linear models are being used in practice for dissolution modeling. Linear 
models include Zero order, Higuchi, Hixson – Crowell, Quadratic and Polynomials, 
where as the nonlinear models include First order, Weibull, KorsMeyer – Peppas, 
Logistic etc. 
There are several linear and non-linear kinetic models to describe release 
mechanisms and to compare test and Reference dissolution profiles are as follows 
 
 Zero order kinetics 
 First order kinetics 
 Korsmeyer-Peppas model 
 Higuchi model 
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Zero order kinetics 
Drug dissolution from pharmaceutical dosage forms that do not disaggregate and 
release the drug slowly (assuming that area does not change and no equilibrium 
conditions are obtained) can be represented by the following equation. 
W0 – Wt= K0t 
 Where,W0  = the initial amount of drug in the pharmaceutical dosage form and 
Wt= the amount of drug in the pharmaceutical dosage form at time t and k is 
proportionality constant.  
This relation can be used to describe the drug dissolution of several types of 
modified release pharmaceutical dosage forms, as in the case of some transdermal 
systems as well as matrix tablets with low soluble drugs, coated forms, osmotic 
systems, etc. the pharmaceutical dosage forms following this profile release the 
same amount of drug by unit of time and it is the ideal method of drug release in 
order to achieve a pharmacological prolonged action. 
 
First order kinetics                                                                       
This type of model to analyze drug dissolution study was first proposed by Gibaldi 
and Feldman and later by Wagner. The relation expressing this model: 
                           Log Qt = Log Q0 + K1t/2.303 
Where,Qt =the amount of drug released in time t, 
 Q0 = initial amount of drug in the solution and K1 is the first order release rate 
constant.  
In this way a graphical relationship between log percent drug remaining versus time 
to get the First order constant from the slope. 
 The pharmaceutical dosage forms following this dissolution profile, such as those 
containing water-soluble drugs in porous matrices release the drug in a way that is 
proportional to the amount of drug remaining in its interior, in such a way, that the 
amount of drug released by unit of time diminishes. 
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KorsmeyerPeppas model 
Korsmeyer et al., (1983) developed a simple semi empirical model, relating 
exponentially the drug release to the elapsed time (t). 
Qt/Qα = Kkt
n
 
 
Where ,Kk = a constant incorporating structural and geometric characteristic of the 
drug dosage form and n is the release exponent , indicative of the drug release 
mechanism. For matrix tablets , an n value of ̃ ~0.5 indicates diffusion – controlled 
mechanism while an n value of ~1.0 indicates erosion. If the value of n is 0.5, it 
indicates Fickian transport, a value of 0.5 >n> 1.0 non-Fickian transport 
combination of both erosion and diffusion controlled release. The values  greater 
than one indicates the drug is releasing by the erosion of polymeric chain. 
 
Table-20: Showing drug mechanism based on release kinetics 
Release exponent (n) Drug transport 
mechanism 
0.5 Fickian diffusion 
0.5<n<1.0 Anomalous transport 
1.0 Case-II transport 
Higher than 1.0 Super Case-II transport 
 
This type of analysis of release behavior is valuable is to the formulator for 
comparative purposes . The Release exponent can be obtained from the slope and 
the Constant (Kk) obtained from the intercept of the graphical relation between 
logarithmic versions of left side of the equation versus log t. 
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Higuchi Model 
Qt= KHt
1/2
 
 
Where,Qt = the amount of drug released at time t and  
            KH = the Higuchi release rate; 
This is the most widely used model to describe drug release from pharmaceutical 
matrices. A linear relationship between the square root of time versus concentration 
indicates that the drug release follows strict Fickian diffusion. 
For purpose of data treatment, the above equation is usually reduced to: 
Q = Kt
1/2
 
                                      Therefore a plot of amount of drug released versus the 
square root of time should be linear if drug release from the matrix is diffusion 
controlled. Alternatively, the drug release rate is proportional to the reciprocal of the 
square root of time. An important advantage of the above equations is its simplicity. 
The order of release and mechanism of release for the optimized formulation were 
reported in table-36 & 38 and fig-20-27. 
 
8.6.9STABILITY STUDIES
(47,48,49,50) 
The stability studies were carried out according to ICH to assess the drug 
formulation stability. Optimized FV formulation was sealed in aluminium packaging 
laminated with polyethylene. Sample were kept at 40 
0
C and 75% RH for 3 months. 
At the end of the study period, the formulation was observed for change in physical 
appearance, color, drug content and drug release characteristics. The values were 
showed in the table-39. 
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9. RESULTS 
 
Table-21API  Characterization for Emtricitabine 
Description White   powder 
Solubility Complies 
Water content(%w/w) 0.5%w/w 
Melting range( 
o
 c) 114.8 to 116.5 
Residue on ignition(%w/w) 0.1 
Heavy metals(ppm) Less than 20%w/w 
Fumaric acid content by potentiometry 
(%w/w) (on anhydrous basis) 
18.7 
S-Isomer content by chiral HPLC (%area) Below quantitation limit 
 
 
Table-22API Characterization for Tenofovir disoproxilfumarate  
Description White   powder 
Solubility Complies 
Water content(%w/w) 0.5%w/w 
Melting range( 
o
 c) 114.8 to 116.5 
Residue on ignition(%w/w) 0.1 
Heavy metals(ppm) Less than 20%w/w 
Fumaric acid content by potentiometry 
(%w/w) (on anhydrous basis) 
18.7 
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9.1 Drug-excipient compatibility Result 
Table-23 Drug-excipient compatibility result(Initial for Emtricitabine and Tenofovir) 
NAME OF THE 
DRUG/EXCIPIENT 
RATIO 
IMP 
A 
IMP 
B 
IMP 
C 
IMP 
D 
IMP 
E 
IMP 
F 
OTHER 
IMP 
TOTAL 
IMP 
Emtricitabine(ECB) 1 0.031 ND 0.220 ND ND ND 0.02 0.271 
Tenofovir Disoproxil 
Fumarate(TDF) 
1 ND ND ND 0.026 0.031 0.021 0.03 0.108 
(ECB+TDF)  + 
DicalciumPhosphate 
1:2 0.050 ND 0.024 0.414 0.112 0.071 0.115 0.786 
(ECB+TDF) + 
MCC PH102 
1:2 0.052 ND 0.027 0.450 0.108 0.082 0.125 0.844 
(ECB+TDF)+ Starch1500 1:1 0.060 ND 0.029 0.411 0,123 0.076 0.111 0.810 
(ECB+TDF)+ 
Lycotab-c 
1:1 0.048 ND 0.015 0.409 0.106 0.081 0.121 0.780 
(ECB+TDF) + HPCLH-11 1:1 0.051 ND 0.016 0.411 0.124 0.061 0.110 0.773 
(ECB+TDF) + Sodium Stearyl 
Fumarate(SSF) 
1:0.1 0.047 ND 0.021 0.419 0.119 0.063 0.103 0.772 
(ECB+TDF) + GlycerylBentonate 1:0.1 0.040 ND 0.012 0.436 0.121 0.062 0.108 0.779 
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                                             Table-24  Drug-excipient compatibility result 14 Days (55°C/60%RH) 
NAME OF THE 
DRUG/EXCIPIENT 
RATIO 
IMP 
A 
IMP 
B 
IMP 
C 
IMP 
D 
IMP 
E 
IMP 
F 
OTHER 
IMP 
TOTAL 
IMP 
Emtricitabine(ECB) 1 0.031 ND 0.022 ND ND ND 0.02 0.073 
Tenofovir Disoproxil 
Fumarate(TDF) 
1 ND ND ND 0.034 0.039 0.040 0.04 0.153 
(ECB+TDF)  + 
DicalciumPhosphate 
1:2 0.051 ND 0.024 0.414 0.112 0.071 0.125 0.797 
(ECB+TDF) + 
MCC PH102 
1:2 0.069 ND 0.030 0.450 0.118 0.094 0.135 0.896 
(ECB+TDF)+ Starch1500 1:1 0.076 ND 0.031 0.423 0,138 0.079 0.133 0.880 
(ECB+TDF)+ 
Lycotab-c 
1:1 0.054 ND 0.021 0.417 0.138 0.084 0.129 0.843 
(ECB+TDF) + HPCLH-11 1:1 0.056 ND 0.019 0.414 0.142 0.076 0.129 0.836 
(ECB+TDF) + Sodium Stearyl 
Fumarate(SSF) 
1:0.1 0.048 ND 0.027 0.421 0.133 0.072 0.113 0.814 
(ECB+TDF) + 
GlycerylBentonate 
1:0.1 0.047 ND 0.021 2.123 0.130 0.079 0.120 2.520 
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 Table-25Drug-excipient compatibility result 28  Days (40°C/75%RH) 
NAME OF THE 
DRUG/EXCIPIENT 
RATIO 
IMP 
A 
IMP 
B 
IMP 
C 
IMP 
D 
IMP 
E 
IMP 
F 
OTHER 
IMP 
TOTAL 
IMP 
Emtricitabine(ECB) 1 0.031 ND 0.220 ND ND ND 0.02 0.271 
Tenofovir Disoproxil 
Fumarate(TDF) 
1 ND ND ND 0.026 0.031 0.021 0.03 0.108 
(ECB+TDF)  + 
DicalciumPhosphate 
1:2 0.050 ND 0.024 0.414 0.112 0.071 0.115 0.786 
(ECB+TDF) + 
MCC PH102 
1:2 0.055 ND 0.029 1.300 0.110 0.089 0.131 1.714 
(ECB+TDF)+ Starch1500 1:1 0.059 ND 0.025 0.421 0.146 0.083 0.139 0.873 
(ECB+TDF)+ 
Lycotab-c 
1:1 0.055 ND 0.016 0.419 0.134 0.081 0.127 0.832 
(ECB+TDF) + HPCLH-11 1:1 0.054 ND 0.022 0.419 0.127 0.075 0.110 0.807 
(ECB+TDF) + Sodium Stearyl 
Fumarate(SSF) 
1:0.1 0.050 ND 0.029 0.425 0.128 0.079 0.111 0.822 
(ECB+TDF) + 
GlycerylBentonate 
1:0.1 0.049 ND 0.027 1.251 0.123 0.064 0.109 1.623 
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                     IMPURITIES: 
EMTRICITABINE  
    IMP A-Sulfoxide I 
    IMP B-Sulfoxide II 
    IMP C-5 Flurocytosine 
 
TENOFOVIR DISOPROXIL FUMARATE 
    IMP D-Monoester 
    IMP E-Adenine 
    IMP F-Isopropyl  
 
 
ND  : Not Detected.   
ECB  : Emtricitabine 
TDF  : Tenofovir Disoproxil Fumarate 
HPCLH-11 : HydroxyPropyl Cellulose LH-II. 
SSF  : Sodium Steryl Fumarate. 
MCC  : Micro Crystalline Cellulose
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Table-26 Drug-excipients compatibility Result by Appearance 
 
NAME OF THE 
DRUG/EXCIPIENTS 
 
RATIO 
DESCRIPTION 
 
INITIAL 
14  Days 
(55°C/60%RH) 
28  Days 
(40°C/75%RH) 
Emtricitabine(ECB) 1 Off White No Change No Change 
Tenofovir Disoproxil 
Fumarate(TDF) 
1 Off White No Change No Change 
(ECB+TDF)  + 
DicalciumPhosphate 
1:2 Off White No Change No Change 
(ECB+TDF) + 
MCC PH102 
1:2 Off White No Change No Change 
(ECB+TDF)+ 
Starch1500 
1:1 Off White No Change No Change 
(ECB+TDF)+ 
Lycotab-c 
1:1 Off White No Change No Change 
(ECB+TDF) + 
HPCLH-11 
1:1 Off White No Change No Change 
(ECB+TDF) + Sodium 
Stearyl Fumarate(SSF) 
1:0.1 Off White No Change No Change 
(ECB+TDF) + 
GlycerylBentonate 
1:0.1 Off White No Change No Change 
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9.2Calibration Curve of Emtricitabine and Tenofovitdisoproxilfumarate. 
 
Table-27 Standard graph for Emtricitabine and Tenofovir 
Concentration(ug/ml) Emtricitabine Absorbance Tenofovir Absorbance 
5 0.11 0.096 
10 0.212 0.186 
15 0.32 0.287 
20 0.425 0.374 
25 0.534 0.475 
30 0.623 0.564 
 
 
Figure-6   Calibration curve for EMT
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Figure-7  Calibration curve for Tenofovir Disoproxil Fumarate.
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9.3 Evaluation of Lubrication Blend For Formulations 
 
 
Table-28  Lubricated blend parameters 
 
 
 
 
Formula 
Angle of 
Repose 
Bulk 
density 
g/ml 
Tapped 
density g/ml 
Compressibility    
Index % 
Hausner 
Ratio 
F1 35.89 0.57 0.67 14.923 1.175 
F2 33.72 0.56 0.67 16.417 1.196 
F3 22.61 0.54 0.64 15.625 1.185 
F4 23.12 0.53 0.66 19.696 1.245 
F5 24.57 0.53 0.64 17.187 1.207 
F6 22.98 0.55 0.67 17.910 1.218 
F7 23.14 0.56 0.66 15.151 1.178 
F8 22.85 0.54 0.64 15.625 1.185 
F9 23.08 0.57 0.65 12.307 1.140 
F10 22.83 0.56 0.65 13.846 1.160 
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9.4DRUG CONTENT 
FORMULATION (F3) 
Assay 
Emtricitabine =97.6 % w/w 
Tenofovir disoproxil fumarate=98.8 % w/w 
 
FORMULATION (F4) 
Assay 
Emtricitabine =97.9 % w/w 
Tenofovir disoproxil fumarate=98.2% w/w 
 
FORMULATION (F5) 
Assay 
Emtricitabine =98.7 % w/w 
Tenofovir disoproxil fumarate=99.6 % w/w 
 
FORMULATION (F6) 
Assay 
Emtricitabine =97.5 % w/w 
Tenofovir disoproxil fumarate=98.9 % w/w 
 
FORMULATION (F7) 
Assay 
Emtricitabine =99.2 % w/w 
Tenofovir disoproxil fumarate=101.8 % w/w 
 
 
FORMULATION (F8) 
Assay 
Emtricitabine =101.9 % w/w 
Tenofovir disoproxil fumarate=102.1 % w/w 
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FORMULATION (F9) 
Assay 
Emtricitabine =99.7 % w/w 
Tenofovir disoproxil fumarate=100.6 % w/w 
 
FORMULATION (F10) 
Assay 
Emtricitabine =101.7 % w/w 
Tenofovir disoproxil fumarate=102.6 % w/w 
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Figure-8 .Assay of Blank 
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Figure-9. Sample Injections 1 to 4 
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Figure-10.Sample Injections 5 to 6 and Peak results of emtricitabine 
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Figure-11:  Peak results of Tenofovir disoproxil fumarate 
 
 
 
 
Figure-12: Assay of Standard 
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9.5 Evaluation Of Core Tablets 
 
Table-29Core tablet parameters 
Formula 
 
Weight 
(mg) 
Thickness 
(mm) 
Hardness 
(kg) 
Friability 
(%w/w) 
 
 
Disintegtratio
n time(min) 
 
F3 998± 1.0 6.90 ±0.5 24.1 ± 0.4 0.030 ± 0.01 
27 min 48 sec  
± 2 sec 
F4 1001± 0.5 6.93 ±0.5 23.7 ± 0.5 
0.034  ± 
0.05 
26 min 38 sec  
± 3 sec 
F5 1004± 0.4 6.96  ±0.5 23.5 ± 0.3 0.035 ± 0.05 
22min 28 sec  ± 
3 sec 
F6 995 ± 1.5 6.98 ±0.8 23.1 ± 0.5 0.039 ± 0.07 
25min 48 sec  ± 
4 sec 
F7 
 
1011± 1.0 
 
6.99 ± 0.5 
 
22.9 ± 0.3 
 
0.034±0.03 
21min 57 ± 2 
sec 
F8 1000± 1.5 7.09±0.4 22.3 ± 0.5 0.048 ± 0.03 
7min 38 sec  ± 
3 sec 
F9 
999 ± 0.5 
 
7.03 ± 0.5 22.1 ±0.5 0.045 ±0.05 
13min 57 ±5 
sec 
F10 1013± 0.5 7.01 ± 0.5 22.4 ±0.5 0.043 ±0.05 
7 min 34 sec  ± 
3 sec 
 
 
 
 
 
113 
 
9.6Evaluation Of  CoatedTablets 
 
Table-30   Coated tablet parameters 
 
 
 
 
 
 
 
 
Formula 
 
Weight 
(mg) 
Thickness 
(mm) 
Hardness 
(kg) 
Disintegtration 
time(min) 
F3 1030 ± 1.5 7.4 ±0.5 25.4 ± 0.4 
29min 26 sec  ± 
2.0 sec 
F4 1033 ± 0.8 7.4 ±0.9 24.9 ± 0.5 
28min 10 sec  ± 
3.0 sec 
F5 1028± 1.7 7.3  ±0.7 24.5 ± 0.3 
24 min10 sec  ± 
7 sec 
F6 1026 ± 2.5 7.3 ±0.4 24.4 ± 0.5 
27 min15 sec  ± 
1.0 sec 
F7 1035 ±1.2 7.4 ±0.5 
 
24.1 ± 0.3 
23min 40 sec ± 
5sec 
F8 1034 ± 1.0 7.5  ±0.5 23.8 ± 0.5 
9min 30 sec  ± 6 
sec 
F9 1033 ±2.5 7.5 ±0.3 23.6 ±0.5 
15min 54 sec ± 
5sec 
F10 1032 ±1.5 7.6 ±0.8 23.9 ±0.5 
9min 22 sec ± 
3sec 
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Figure-13 Coated Tablets Thickness of Different Formulations 
 
 
 
Figure-14 Coated Tablet Hardness Of Different Formulations 
 
 
 
 
 
7.1
7.2
7.3
7.4
7.5
7.6
7.7
7.8
F3 F4 F5 F6 F7 F8 F9 F10
Th
ic
kn
e
ss
Formulations
22.5
23
23.5
24
24.5
25
25.5
26
F3 F4 F5 F6 F7 F8 F9 F10
H
ar
d
n
e
ss
Formulations
115 
 
Figure-15 Coated Tablet Disintegration Time oF Different Formulations 
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9.7 Dissolution Profile 
 
Table-31In-vitro drug Release Profile 
forINNOVATOR(Emtricitabine) 
 
 
 
 
 
 
 
 
 
   
 
Figure-16   In vitro drug release profile of Innovator(Emtricitabine) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Time(Minutes) 
Cumulative Percentage 
Drug Release of Emtricitabine 
0 0 
5 31.0 
10 64.4 
15 73.3 
30 97.0 
45 98.0 
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Table-32In-vitro drug Release Profile for INNOVATOR product                                                                                                                             
(Tenofovir  disoproxil -fumarate) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure-17In vitro drug release profile of Innovator(Tenofovir)  
 
 
 
 
 
 
 
 
Time 
(Minutes) 
Cumulative Percentage 
Drug Release of 
Tenofovir disoproxil 
fumarate 
0 0 
5 33 
10 65.8 
15 73.9 
30 95.6 
45 96.8 
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Table-33In-vitro release of Emtricitabine of formulations 
Time 
(min) 
Cumulative % Drug release 
F3 F4 F5 F6 F7 F8 F9 F10 
0 0 0 0 0 0 0 0 0 
5 20 21 22.4 22 24.1 34 32.5 33.2 
10 33.9 34.1 35.1 34.9 36.8 68.1 63.4 66.3 
15 41.5 42.4 45.4 44.1 47.5 83.4 78.1 84.1 
30 67.9 68.3 70.3 69.8 72.6 97.1 93.8 97.4 
45 86.9 87.2 89.1 88.3 92.1 99.8 95.9 99.8 
 
Figure-18DissolusionOf Emtricitabine Formulations  
With Innovator 
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Table-34In-vitro release of Tenofovir disoproxil fumarate 
formulations 
Time 
(min) 
Cumulative % Drug release 
F3 F4 F5 F6 F7 F8 F9 F10 
0 0 0 0 0 0 0 0 0 
5 20.0 20.2 21.8 21.4 25.6 31.4 26.7 28.3 
10 31.6 32.4 36.7 35.1 39.5 65 57.6 62.3 
15 43.9 44.3 51.2 47.3 57.8 73.9 64.6 74.1 
30 59.3 61.3 69.7 63.8 71.4 98.1    76.2 98.3 
45 82.1 82.7 88.6 84.7 90.9 98.8 95.3 98.8 
           
 
 
Figure-19Dissolusion Of Tenofovir Disoproxil Fumarate 
Formulations  with Innovator 
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9.8kinetic Release Profile Data For Optimization Batch(F8) 
 
Table 35  Kinetic values of Emtricitabine 
 
 
Figure20: Zero order plot(Emtricitabine) 
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Square 
root of 
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Log 
time 
Cum % 
drug 
release 
Log 
Cum 
% 
drug 
release 
Cum % 
drug 
remaining 
Log Cum 
% drug 
remaining 
1 0 0 0 0 0 100 2 
2 5 2.23 0.698 34 1.53 66 1.82 
3 10 3.16 1 68.1 1.83 31.9 1.50 
4 15 3.87 1.17 83.4 1.92 16.6 1.22 
5 30 5.48 1.47 97.1 1.98 2.9 0.46 
6 45 6.71 1.65 99.8 1.99 0.2 -0.69 
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Figure 21:First order plot(Emtricitabine) 
 
 
 
Figure 22:Higuchi  plot (Emtricitabine) 
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Figure23:Korsmeyerpeppas  plot (Emtricitabine) 
 
 
 
 
Table 36: Kinetics values obtained different plots of  
Formulation (F8) of Emtricitabine. 
 
Formulation 
Zero order 
plot(R
2
) 
First order 
plot(R
2
) 
Higuchi plot 
(R
2
) 
Korsmeyer 
plot(R
2
) 
R
2 
N 
F8 0.7669 0.9889 0.9436 0.8555 1.1948 
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Table 37:  Kinetc values of Tenofovir Disoproxil Fumarate 
S.no Time(min) Square 
root of 
time 
Log 
time 
Cum % 
drug 
release 
Log 
Cum 
%drug 
release 
Cum % 
drug 
remaining 
Log Cum 
% drug 
remaining 
1 0 0 0 0 0 100 2 
2 5 2.23 0.69 31.4 1.49 68.6 1.83 
3 10 3.16 1 65 1.81 35 1.54 
4 15 3.87 1.17 73.9 1.86 26.1 1.41 
5 30 5.48 1.47 98.1 1.99 1.9 0.27 
6 45 6.71 1.65 98.8 1.99 1.2 0.07 
 
 
 Figure 24: Zero order plot(Tenofovir Disoproxil Fumarate)
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Figure 25: First order plot (Tenofovir Disoproxil Fumarate) 
 
 
 
Figure 26: Higuchi order plot (Tenofovir Disoproxil Fumarate) 
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Figure 27:  Korsmeyer  plot (Tenofovir Disoproxil Fumarate) 
 
  
 
 
 
Table 38: Kinetics values obtained from different plots of 
formulation (F8) ofTenofovir Disoproxil Fumarate. 
Formulation 
Zero order 
plot(R
2
) 
First order 
plot(R
2
) 
Higuchi plot 
(R
2
) 
Korsmeyer plot(R
2
) 
R
2 
N 
F8 0.7020 0.9809 0.9105 0.8401 1.1952 
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9.9  STABILITY STUDIES 
                              Condition: 25°C/60%RH 
                      40°C/75%RH  
Table-39:  Stability Studies 
S.N
o 
 
Parameters 
Conditions  
Initial 
40C& 
75%RH 
40C& 
75%RH 
40C& 
75%RH 
0 Day 1 month 2 month 3 month 
1 
Average 
weight 
1030±5(mg) 1030±5(mg) 1030±5mg 1030±5mg 
2 
Thickness(mm
) 
7.4±0.9 7.4±0.9 7.4±0.8 7.4±0.8 
3 Hardness(kg) 24.0±0.5 25.0±0.4 25.0±0.1 25.0±0.1 
4 
Disintegration(
min) 
9min10sec 11min09sec 11min03sec 11min03sec 
5 
Dissolution(45
min) 
99.7,95.8 99.6,95.8 99.4,95.2 99.2,95.0 
6 Assay(%) 
99.8,100.9(
%w/w) 
99.8,100.9(%
w/w) 
99.7,100.2(%
w/w) 
99.7,99.98(%
w/w) 
 
 
S.no Parameters 
Initial 25
0
C&60%RH 
0 Day 3 month 
1 Average weight 1030±5(mg) 1030±5mg 
2 Thickness(mm) 7.4±0.9 7.4±0.8 
3 Hardness(kg) 24.0±0.5 25.0±0.3 
4 Disintegration(min) 9min10sec 11min09sec 
5 Dissolution(45min) 99.7,95.8 99.4,95.9 
6 Assay(%) 99.8,100.9(%w/w) 99.7,100.8(%w/w) 
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10. DISCUSSION 
The prepared granules were evaluated for the angle of repose which was ranged 
from 35.89 to 22.83 for the different formulation, the bulk density was found to be  
0.57 to o.53 and the hausner‟s ratio was ranged from 1.245 to 1.140. 
The drug content was analyzed by using HPLC the readings were as per I.P limit 
ranging from 97.6%w/w to 102.1 % w/w.   
Formulations (F1, F2, F3) are prepared for the selection of the process. The . 
formulation F1 was not selected due to high angle of repose value(35.89). the result 
revealed that the powder blend  may not be suitable for the direct compression 
method.    
The granules of formulation f2 was prepared by dry granulation method and the 
results was found  low granules strength. the result revealed that the powder blend  
may not be suitable for the dry granulation method.    
 the granules of formulation F3  was prepared by wet granulation. water is used as a 
vehicle.the result of granules were found  Good strength, flow property but 
impurities like monoesters were formed above the limit (1.4%). The disintegration 
time was found to be 29 min 26 sec with starch 1500(10%) as disintegrant and the 
percentage of drug release at the end of 45 min of Emtricitabine and Tenofovir 
disoproxil fumarate was found to be  82.1% and 86.9%. The results found were not 
matching with the innovator.  
So in the next formulation F4, the vehicle was changed to mixture of IPA and Water 
(80:20). With this the impurities formed was reduced to 0.562%. But there is not 
much change in disintegration time and %of drug release than with formulation F3 
where starch (10%) was used as a disintegrant for both. 
So, for further formulations F5-F10 the same wet granulation with IPA and water 
(80:20) was selected . But to reach the target disintegration time (11min 30 sec) and 
%of drug release (98% for ECB and 96.8% TDF) as that of innovator  
differentdistintegrants ( starch 1500, lycatab C, HPCLH-11) with different 
concentration (8%, 10% and 12%)  was used. 
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In the formulation F5 Starch1500 (12%) was used. The disintegration time was 
found to be 27 min 38 sec. The percentage of drug release of Emtricitabine and 
Tenofovir disoproxil fumarate was found to be 89.1% and 88.6% . 
To increase the drug release and to decrease the disintegration time the formulation 
F6 was prepared  by changing the disintegrate to Lycatab-c (10%). The 
disintegration was found to be 25 min 48 sec and the percentage of drug release was 
found to be 88.3% for EMB and 84.7% for TDF. Further in the formulation F7 the 
concentration of Lycatab C was increased to 12%. The disintegration time was 
found to be 23min 40 sec and the percentage of drug release was found to be 92.1% 
for EMB and 90.9% for TDF. Though, the percentage of drug release was increased 
but not matching with the innovator. 
In the formulations F8,F9& F10 HPCLH-11 was used as a disintegrant at 10%,8% 
and 12% respectively. The disintegration time for F8 was found to be 7 min 38 sec, 
for F9 was found to be 13 min 57 sec, and for F10 was found to be 7 min 34 sec. 
The percentage of drug release for EMB was found to be 99.8%, 95.9%, 99.8% and 
for TDF it was found to be 98.8%, 95.3%, 98.2% for formulation F8,F9 and F10 
respectively. This may be due to the wicking power of  hydrophilic polymer- 
HPCLH-11. 
The formulation F8 and F10 disintegration times and percentage of drug release 
reached the target innovator.  So, the formulation F8 with concentration 10% of 
HPCLH-11 was selected as optimized formulation and further mechanism of drug 
release was calculated for formulation F8. 
Results of the kinetics of drug release shows that both the drugs EMB and TDF were 
best fit into the first order kinetics. Korsmeyerpeppas was calculated to find out the 
mechanism of release. The n values was found to be 1.1952 for EMB and1.1948 for 
TDF it indicates non-fickian super case II transport so, the drug release may be by 
the erosion of polymeric chain.  
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Stability studies were performed for a period of 3 months. Samples are analysed 
initial 1
st
 month 2
nd
 month and 3
rd
 month storing the tablets at 40
0
C  and 75% RH. 
At 25
0
C & 60% RH the samples were analysed. It was found that ther was no 
physical and chemical change based on initial data. 
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                        11. SUMMARY AND CONCLUSION 
SUMMARY 
             The main aim of the present study is to develope and evaluates 
Emtricitabine combination with tenofovir disoproxil fumarate comparable to the 
marketed product. 
The compatibility test shows no intraction with the drug and excipients . The process 
selected was wet granulation. The formulations was  optimized by using different 
disintegrants (Starch1500,Lycatab C and HPCLH-11) at different concentrations 
(8%,10%&12%). All the formulations were evaluated for physical characteristics, 
disintegration, invitro dissolution and stability studies. Based on results formulation 
F8 with HPCLH-11(10%) selected as best formulation since it matches with 
innovator product. 
            Stability studies were performed for these batches 1-3 months under 
accelerated and long term testing conditions. During that period the product was 
analysed for physical appearance, hardness, thickness, friability, dissolution, assay 
and related substances. The results were found to be within the specified limit. 
           The selection of manufacturing process to the finalization of pack has been 
done in according with recognized principles of current good manufacturing process 
and relevant FDA guidelines and pharmacopoeia.  
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CONCLUSION 
The immediate release tablets of Emtricitabine combination with Tenofovir 
disoproxil fumarate have been developed with wet granulation method with serial 
increasing Disintegrant concentration ratio in each subsequent batch. And it is 
compared with that of Marketed(Truvada) tablets. Various trials were performed to 
get the optimized formula with Disintigrent HPCLH-11. Among all the design 
formulations F8 is showing optimized (acceptable) results within USP limits. There 
is no undesirable change is found in accelerated stability condition for 1&3 months 
in optimized formulated batch. 
       From the above all Formulations and observations we conclude that batch no F8 
is showing result with in USP limits and same like Innovator. So further in vivo 
studies can be performed 
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